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ABSTRACT 
___________________________________________________________________ 
Background: The t(8;14) translocation in Burkitt’s lymphoma (BL) was the first 
non-random cytogenetic lesion to be described in lymphoproliferative 
disorders. This lesion occurs in 75-85% of all BL cases. However, the 
breakpoints in this cytogenetic lesion are very variable and far apart such that 
the t(8;14) translocation is not always amenable to standard polymerase chain 
reaction analysis. This is mainly due to the inability of the Thermus aquaticus 
(Taq) polymerase enzyme to synthesize long DNA products. Long range 
polymerase chain reaction (LD-PCR) with a high fidelity polymerase enzyme 
mix capable of longer PCR product synthesis has recently become available. 
In early studies, LD-PCR appeared to be capable of amplifying the t(8;14) 
translocation in the majority of published sporadic Burkitt’s lymphoma 
analyses. The utility of t(8;14) translocation LD-PCR for routine use in the 
diagnosis of BL in our setting has not yet been studied. The aim of this study 
was to establish and optimize the t(8;14) LD-PCR technique and to apply it in 
the retrospective analysis of all BL diagnosed in the University of the 
Witwatersrand teaching hospitals in a ten year period from January 1994 to 
December 2003. 
Materials and methods: High molecular weight non-degraded DNA was 
extracted from control cell lines as well as stored, unstained bone marrow 
slides remaining after routine diagnostic workup of previously identified 
Burkitt’s lymphoma patients. Three hundred nanograms of patient and control 
DNA were amplified with the LD-PCR high fidelity polymerase enzyme mix 
under reaction conditions which were optimized using the tissue plasminogen 
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activator (tPA) gene as well as known Burkitt’s lymphoma cell lines as controls. 
Each control and patient DNA sample was amplified with tPA primers as well 
as four pairs of MYC/IgH primer sets. The resulting amplicons were size 
fractionated on an agarose gel and visualized with ethidium bromide under 
ultraviolet (UV) light. The fractionated DNA fragment sizes were compared to 
those of the t(8;14) translocation positive controls, tPA controls and known 
DNA molecular weight markers. 
Results: One hundred and ten Burkitt’s lymphoma diagnoses were made in 
the three teaching hospitals of the University of the Witwatersrand from 
January 1994 to December 2003. Bone marrow involvement by BL was 
present in 84 of these cases. Archival bone marrow slides were available in 74 
of the 84 BL patients. Intact high molecular DNA on which the t(8;14) LD-PCR 
analysis could be performed was present in 41 of the 74 BL patients. In the 
presence of appropriate controls, an t(8;14) translocation specific product was 
demonstrable by t(8;14) LD-PCR analysis in only 6 of 41 BL patients.           
Conclusion: In this t(8;14) LD-PCR retrospective analysis of a large number 
known Burkitt’s lymphomas, the diagnostic yield in carefully selected  patients 
was extremely poor. With five primer pairs required per BL sample analysis, 
this technique was found too labour intensive and costly in our hands making it 
unsuitable for routine diagnostic use. The reasons for the poor diagnostic yield 
remains unclear and may need to be explored in future studies. Emerging 
alternative techniques for the diagnosis of BL such as fluorescence in situ 
hybridization and microarray gene expression analyses may prove to be better 
diagnostic tools than LD-PCR in its current form. 
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CHAPTER 1 
1.0      OVERVIEW OF BURKITT’S LYMPHOMA AND LITERATURE REVIEW.  
1.1 General introduction to Burkitt’s lymphoma.  
 
Burkitt’s lymphoma (BL) is a B-cell Non-Hodgkin’s lymphoma (B-NHL) characterized  
clinically by extranodal disease presentation with rapid progression,  morphologically 
by small, non-cleaved lymphoid malignant cells and genetically by a non-random 
translocation involving the c-myc gene and immunoglobulin heavy chain or light chain 
gene loci (Harris, Jaffe et al. 1994; Harris, Jaffe et al. 2000). This high grade B-cell 
NHL was first described by Dennis Burkitt in 1958 as a tumor with predilection for the 
jaw and with high frequency in the equatorial Africa region (Burkitt 1958). It is now well 
established and accepted that BL occurs frequently outside the geographic and 
anatomic locations of it’s original description (Magrath 1991; Mwanda, Rochford et al. 
2004).  
 
The genetic hallmark of BL is exchange of chromosomal material between the myc 
gene on chromosome 8 and one of the immunoglobulin genes on chromosome 2, 14 
or 22. This is a balanced translocation in which material is lost and gained by both 
chromosomes as schematically illustrated in Figures 1.1 and 1.6 below. The resulting 
fused DNA segments have 3’-3’ and 5’-5’ orientations and therefore biologically not 
functional.  No fusion trnascript is generated from the chromosomal trnaslocation, the 
MYC/IgH rearrnagement can only be detected at genomic DNA level. Of the three 
possible translocations, namely, t(2;8), t(8;14) and t(8;22), the t(8;14) is the most 
common, occurring in more than 75% of all BL cases (Braziel, Arber et al. 2001; 
Burmeister, Schwartz et al. 2005; Dave, Fu et al. 2006). 
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Whilst its cytomorphology suggests a single homogenous entity, BL displays 
significant heterogeneity in its epidemiology, clinical phenotype and molecular genetic 
features. The clinical varieties of BL, which initially included only the endemic (eBL) 
and sporadic (sBL) forms, have been expanded in the newer classifications of 
lymphomas. The Revised European American Lymphoma (REAL) classification 
recognized at least three BL variants, namely, the endemic BL (eBL), the sporadic 
BL(sBL) and a provisional entity of Burkitt’s-like lymphoma(BLL) (Harris, Jaffe et al. 
1994). Burkitt-like lymphoma was largely a morphologic entity in contradistinction to 
eBL and sBL which are true clinico-epidemiological variants(Bouffet, Frappaz et al. 
1991; Hecht and Aster 2000).   
 
The REAL classification of lymphomas has now been superseded by the current 
World Health Organization (WHO) classification of haematolymphoid malignancies 
(Harris, Jaffe et al. 2000). In this classification, BL is categorized as a single clinico-
pathological entity incorporating morphologic variants as well as clinical and genetic 
subtypes.  
 
The morphologic variants include the classic BL morphology, the Burkitt’s-like 
lymphoma and the BL with plasmacytoid differentiation associated with the acquired 
immunodeficiency syndrome (BL-AIDS). The morphologic differentiation of these 
entities is outlined in section 1.5 below.  
 
The clinical and genetic subtypes include the clinico-epidemiologically defined entities 
of eBL, sBL and AIDS-related BL (AIDS-BL). Current research is directed towards 
distinguishing these entities further at molecular level. Early indications suggests that 
they have different pathogenetic mechanisms and molecular lesions (Bellan, Lazzi et 
al. 2003; Burmeister, Schwartz et al. 2005; Stein and Hummel 2007). Some of the 
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different locations of breakpoints in the various BL subtypes are illustrated in Figure 
1.7 below. Juxtaposition of the IgH gene enhancer on chromosome 14 and c-myc 
gene on chromosome 8 drives the c-myc overexpression in BL.  
  
 
Figure 1.1   Chromosomal translocations in BL. Shown above are the three 
chromosomal translocations that may independently occur in Burkitt’s 
lymphoma. In each case, the c-myc gene on chromosome 8 is translocated to 
the enhancer region of an immunoglobulin gene on any one of chromosome 2, 
14, or 22. The distal part of these chromosomes is then reciprocally 
translocated to chromosome 8. The t(8;14) occurs in the majority of BL cases. 
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1.2 Overview of contribution of BL to pathology and oncology. 
 
In the four decades since its first description by Dennis Burkitt, BL has had a 
significant influence on our understanding of the molecular basis of disease offering a 
number of innovative concepts linking molecular lesions with clinical phenotype. 
Recent molecular studies using microarray technology suggest that BL is probably 
going to continue to lead the way in linking molecular signatures with pathological 
entities(Dave, Fu et al. 2006; Hummel, Bentink et al. 2006). Some of these 
contributions are outlined in Table 1.1. 
 
Table 1.1   Contribution of Burkitt’s lymphoma to oncology and pathology. 
 
Burkitt’s Lymphoma Contribution 
 
Contributing Author(S) And Date 
1. The first human malignancy shown to 
be associated with a virus as a 
potential aetiologic agent 
 
(Epstein, Barr et al. 1964) 
2. The first tumor in which surface 
membrane immunoglobulins were 
described  
 
(Clifford, Singh et al. 1967; Klein, Clifford 
et al. 1967) 
3. The first human tumor potentially 
curable by chemotherapy alone 
 
(Burkitt 1967) 
4. The first lymphoma described to be  
      associated with a non-random   
      chromosomal translocation 
 
(Manolov and Manolova 1972) 
5. The first lymphoma shown to be  
     associated with AIDS 
 
(Chaganti, Jhanwar et al. 1983) 
6. Probably the first lymphoproliferative 
    disorder to have a microarray  
    molecular  classification
(Dave, Fu et al. 2006) 
 
Burkitt’s lymphoma was the first tumor in which surface membrane 
immunoglobulin(SMIG) was described and reported (Klein, Clifford et al. 1966; Klein, 
Clifford et al. 1967). Since this discovery, SMIG have become important targets used 
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in the diagnosis of B-cell malignancies. They are critical to our understanding of the 
pathophysiology of B-cell malignancies and provide a useful approach to their 
differential diagnoses (Holowiecki, Lutz et al. 1979; Naeim, Bergmann et al. 1979; 
Kuroyanagi and Kura 1981; Zucchetto, Sonego et al. 2005).   
 
Burkitt’s lymphoma was the first human malignancy shown to be associated with a 
virus as a potential aetiologic agent(Epstein, Barr et al. 1964; Epstein and Achong 
1973; Epstein and Morgan 1983; Epstein 1988). Since then many viruses of the  
retrovirus and herpes virus families have been shown to be causally linked to a variety 
of human leukemias and lymphomas (Wang, Jeng et al. 2006). These included the 
human T-cell leukemia/ lymphoma virus type 1 (HTLV-1) and the Epstein Barr virus 
(EBV). HTLV-1 is causative agent for adult T-cell leukemia/lymphoma (Saxinger, 
Levine et al. 1985; Ambinder 1990; Ohshima, Suzumiya et al. 2002). The EBV is 
associated with Burkitt’s lymphoma, lymphomas in immunocompromised people as 
well as Hodgkin’s lymphoma (Ambinder 1990; Hirose, Sugai et al. 1999; Crawford 
2001). The discovery of human herpes virus type 8 or Kaposi’s Sarcoma herpes like 
virus (KSHV) has led to the identification of a range of virus-associated 
lymphoproliferative diseases (Ablashi, Easton et al. 1976; Hampl, Conrad et al. 1991). 
These include the body cavity based lymphomas as well as other lymphomas in the 
immunocompromised individuals (Nador, Cesarman et al. 1996; Gaidano, Pastore et 
al. 1997; Arguello, Sgarbanti et al. 2003).  
 
Burkitt’s lymphoma was the first NHL to be described in patients with acquired 
immunodeficiency syndrome (AIDS) (Chaganti, Jhanwar et al. 1983). Recent data 
suggest that hepatitis C virus infection is also associated with an increased incidence 
of lymphoma, whereas data relating to SV40 remains controversial (Franceschi, 
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Polesel et al. 2006; Lizardi-Cervera, Poo et al. 2006; Nieters, Kallinowski et al. 2006; 
Visco, Arcaini et al. 2006).  
 
The first lymphoid tumor in which a non-random chromosomal translocation has been 
linked to be involved in the tumor pathogenesis was BL (Manolov and Manolova 1972; 
Zech, Haglund et al. 1976). To date a number of these non-random translocations 
have become indispensable tools in the diagnosis, grading, prognostication and 
therapeutic outcome evaluation (minimal residual disease) in B-cell and non-B-cell 
malignancies (Rabbitts 1983; Nowell and Croce 1986; Haluska and Croce 1987; 
Gauwerky and Croce 1993; Glassman, Hopwood et al. 2000).  
 
BL was the first human tumor shown to be curable by chemotherapy alone (Burkitt 
1967; Clifford, Singh et al. 1967; Rabbitts 1983; Nowell and Croce 1986; Haluska and 
Croce 1987; Gauwerky and Croce 1993; Glassman, Hopwood et al. 2000). Although 
most human malignancies remain incurable with chemotherapy alone, the BL 
experience has kept this treatment modality at the forefront of therapeutic intervention 
in malignant disorders. With this background, it is therefore not unreasonable to 
speculate that this B-NHL is likely to have considerable impact in our understanding of 
oncology and biomedical research in the years to come.  
  
1.3 Clinico-epidemiological features of Burkitt’s lymphoma. 
1.3.1 General overview of clinico-epidemiological features. 
 
In BL, epidemiology and clinical features are strongly linked and appear to have 
described through a number of phases in the last four decades. Three distinct clinico-
epidemiologic patterns are seen in BL and these have evolved sequentially over time. 
They are underpinned by common morphologic and pathobiological features. Some of 
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the clinico-epidemiologic differences in the various subtypes of BL are summarized in 
Table 1.2 below.   
 
The AIDS associated BL (AIDS-BL) is largely a disease of adults involving both nodal 
and extranodal sites (Diebold, Raphael et al. 1997; Davi, Delecluse et al. 1998; Spina, 
Tirelli et al. 1998; Spina, Simonelli et al. 2005). The eBL and sBL present primarily in 
childhood as extranodal disease with jaw involvement and abdominal presentations 
respectively (Sariban, Donahue et al. 1984; Magrath 1991). Bone marrow involvement 
at presentation occurs more frequently in the AIDS-BL and sBL subtypes compared to 
the eBL (Janus, Edwards et al. 1984; Magrath 1991; Diebold, Raphael et al. 1997; 
Davi, Delecluse et al. 1998). Central nervous system involvement occurs in up to a 
third of patients in all three subtypes of BL and is associated with poor outcome 
following chemotherapeutic intervention (Sariban, Edwards et al. 1983; Saurina, 
Ramirez de Arellano et al. 2001).  
 
1.3.2 Clinico-epidemiological features of eBL. 
 
In the first epidemiologic description in 1958, BL was thought to be a highly 
aggressive malignancy occurring exclusively in young African children and 
geographically confined to the equatorial Lymphoma belt (Burkitt 1969; Burkitt 1971). 
In this geographic region, which was defined as an area approximately 15˚ on either 
side of the equator, the incidence of eBL was high, ranging  from 5 to 15 per 100 000 
children younger than 6 years per year( (Burkitt 1969). Generally the tumor did not 
occur in areas where the mean temperature at any given time was less than 16°C , 
the altitude was less than 1800m and annual rainfall less than 50cm3 (Burkitt 1969; 
Burkitt, Williams et al. 1969). These climatic and geographic descriptions may appear 
to have little relevance to our current understanding of eBL, but were pivotal 
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observations which incriminated a biological organism as a potential causative agent 
of BL. The association of EBV and BL was pursued and ultimately proven on the basis 
of these original important epidemiological observations(Nilsson and Ponten 1975; 
Kaplan, Goodenow et al. 1979).  
 
Table 1.2   Clinico-epidemiological features of BL subtypes. 
 Endemic BL (eBL) 
 
 
Sporadic BL 
(sBL) 
 
AIDS related BL 
(AIDS-BL) 
Geographic 
distribution 
Around Equatorial 
Africa 
Away from  
equatorial Africa  
Mirrors the HIV 
pandemic distribution 
Incidence 5-15/100 000/yr 2-3/100 000/yr 25-35% of B-NHL 
Age Children>adults Children>adults Adults>children 
Lymph node 
involvement Rare Rare Common 
Jaw 
involvement Common Uncommon Uncommon 
Abdominal 
Involvement Common 
More common than 
jaw Common 
Bone marrow 
involvement 10%  30% 30% 
CNS 
involvement 20-30% 20-30% 20-30% 
 
 
The annual incidence of eBL is 2.2 to 3.8 cases per 100 000 inhabitants and the peak 
age is 5-8 years in central Africa and 4-5 years  in north Africa (Hecht and Aster 
2000). In the early studies, BL was found to be commoner in boys with a male to 
female ratio of 2:1. This sex distribution has shown little change over time (Aboulola, 
Boukheloua et al. 1985; Ong, Xue et al. 2001; Mwanda 2004; Mwanda, Whalen et al. 
2005). 
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The clinical features of eBL are distinct as it presents largely as a jaw mass with a 
frequency as high as 60% in some studies (Davies, Elmes et al. 1964; Ong, Xue et al. 
2001; Mwanda 2004; Mwanda, Whalen et al. 2005). The precise cellular origin of the 
jaw mass is unclear, but typically there is involvement of the developing premolar and 
molar teeth.  The maxillae are involved twice as often as the mandibles with orbital 
involvement relatively uncommon (Magrath 1991; Muwakkit, Razzouk et al. 2004; 
Mwanda 2004; Haralambieva, Boerma et al. 2005). Although not often emphasized, 
abdominal involvement in eBL is as common as jaw involvement, occurring in 58% of 
cases (Aboulola, Boukheloua et al. 1985). The retroperitoneum, mesentery and 
omentum are more commonly involved than the actual bowel. Other organs such as 
the kidneys, ovaries, pancreas and adrenal are also frequently involved (Janus, 
Edwards et al. 1984; Magrath, Janus et al. 1984). Bone marrow involvement is 
present in 12% of cases and central nervous system involvement in 30% of cases 
(Sariban, Edwards et al. 1983; Nkrumah, Neequaye et al. 1985). Peripheral lymph 
node involvement is very uncommon, comprising less than 1% of cases at clinical 
presentation (Magrath 1991; Mwanda 2004). 
 
1.3.3 Clinico-epidemiological features of sBL. 
 
Following the original description of eBL in Africa, several pathologists who were 
familiar with the eBL histology, started to recognize tumors which were histologically 
similar to eBL but occurred in Europe and North America (Dorfman 1965; O'Conor, 
Rappaport et al. 1965; Wright 1966). This sporadically occurring BL variant with 
distinct clinico-epidemiological features was therefore called sporadic BL (sBL).  
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The incidence of sBL is much lower than eBL, with reported rates of 2-3 per million of 
the population per year (Magrath 1997; Spina, Tirelli et al. 1998). Similar to eBL, sBL 
is a disease of children and is commoner in boys compared to girls.  
 
Unlike eBL, sBL originates in Peyer’s patches or mesenteric lymph nodes and then 
malignant lymphocytes will home into the follicular B cell zones of abdominal and 
peripheral lymph nodes. It is therefore not surprising that the most frequent clinical 
presentation is abdominal obstruction or discomfort as a result of a large abdominal 
mass (Levine, Connelly et al. 1985; Patton, McMillan et al. 1990; Carbone, Canzonieri 
et al. 2000). Jaw tumors characteristic of the majority of eBL cases, are present in 
only 15% of children with sBL (Patton, McMillan et al. 1990). Bone marrow 
involvement occurs early and is three fold commoner in sBL than eBL. Consequently, 
sBL has a greater propensity for leukemic dissemination. The leukemia associated 
with sBL is of the L3 morphology and is associated with a poor prognosis. Central 
nervous system involvement is common occurring in over 80% of children with a 
median survival of 6 months following treatment with conventional chemotherapy 
(Cairo, Sposto et al. 2003; Jacobsen and LaCasce 2006). 
 
1.3.4 Clinico-epidemiological features of AIDS-BL. 
 
In the era of the HIV pandemic, the frequency of several NHLs was noted to be 
increasing. Burkitt’s lymphoma was the first type of B-NHL reported in HIV infected 
individuals in 1982(Doll and List 1982; Ziegler, Drew et al. 1982). Subsequent clinico-
epidemiological studies, however, have demonstrated that BL is less common than 
diffuse large B cell non-Hodgkin’s lymphoma and accounts for 30% of NHL associated 
with AIDS (Beral, Peterman et al. 1991). Burkitt’s lymphoma associated with AIDS 
may be the first manifestation of the disease in a significant number of cases and this 
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has been shown to develop in the presence of relatively well preserved CD4 counts 
(Boyle, Swanson et al. 1990; Beral, Peterman et al. 1991; Roithmann, Tourani et al. 
1991; Carbone, Gloghini et al. 1995). As HIV infected individuals live longer as a 
result of Highly active anti-retroviral therapy (HAART), the number of AIDS related 
NHLs , including BL, is expected to rise several fold. 
 
The clinical presentation of AIDS-BL is often extranodal with gastrointestinal tract, 
bone marrow and liver involvement being common (Spina, Tirelli et al. 1998; Carbone 
and Gloghini 2005; Lim, Karim et al. 2005; Navarro and Kaplan 2006). 
 
1.4 The Changing morphologic classification of Burkitt’s lymphoma.  
 
Our understanding of pathology and molecular biology of BL has been changing 
largely as a result of innovations and advances in diagnostic technology but also due 
to acquisition of new knowledge and molecular insight of pathology of 
lymphoproliferative disorders. Over the last four decades, the BL morphologic 
classification has evolved from simple morphologic and histopathologic descriptions to 
characterizations which include aspects of immunophenotypic, cytogenetic, and 
molecular analysis of the disease.  
 
Changes in Burkitt’s lymphoma classification are reflected in each of the major 
international classifications of lymphoproliferative disorders. The six major 
classifications included the Rappaport, the Lukes and Collins, the International 
Working Formulation, the Kiel, the Revised European American Lymphoma (REAL) 
and more recently the World Health Organization classification. The Burkitt’s 
lymphoma description in each of the major classifications of lymphoproliferative 
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disorders is briefly outlined below. The changing descriptive terminology of BL in the 
various classifications are also summarized in table 1.3 below. 
 
1.4.1 Rappaport classification. 
 
In the original Rappaport classification of NHL of 1966, BLs were described as 
“undifferentiated cell type” because of their non-resemblance to either lymphoid or 
histiocytic differentiated cells (Rappaport 1966; Byrne 1977). In 1967, an expert 
committee commissioned by the WHO, convened to establish whether BL was a 
clinical syndrome, a clinicopathologic syndrome or a pathological entity. The 
committee established that BL was a separate pathological entity and suggested the 
term ”malignant lymphoma, undifferentiated, Burkitt’s type” (Carbone, Berard et al. 
1969). The term “undifferentiated” was used to denote a morphological rather than an 
immunobiologic concept. This term had no immunological connotation at that stage as 
most immunological markers of differentiation were not yet identified. The Rappaport 
classification was superseded by the Lukes and Collins classification. 
 
1.4.2 Lukes and Collins classification. 
 
Lukes and Collins in their lymphoma classification of 1974, suggested that BL was of 
follicular centre origin and proposed the term “small non-cleaved lymphoma” to define 
this entity (Lukes and Collins 1974). At that stage it was well established that BL was 
of lymphoid lineage and not truly undifferentiated as previously suggested in the 
Rappaport classification. The small non-cleaved terminology first introduced in this 
classification, has remained the fundamental classic morphologic description for BL. 
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Table 1.3   BL description in the various lymphoma classifications† 
LYMPHOMA 
CLASSIFICATION 
BURKITT’S LYMPHOMA  
DESCRIPTION 
YEAR OF 
DESCRIPTION 
Rappaport  
classification 
Malignant lymphoma, 
Undifferentiated, Burkitt   type 1966 
Lukes and Collins 
classification Small non-cleaved lymphoma 1974 
International working 
formulation classification 
Small non-cleaved lymphoma, 
Burkitt’s type 1982 
Kiel classification B-lymphoblastic lymphoma, small non-cleaved cell type 1988 
Revised European 
American classification 
Mature B-cell lymphoma, small 
non-cleaved, Burkitt 1994 
World Health Organization Mature B-cell lymphoma, classic Burkitt 2001 
† Only descriptions of classic BL are included in this table. Atypical subtypes and variants 
excluded. 
 
1.4.3 International working formulation (IWF) classification. 
 
The International working formulation was a National Cancer Institute sponsored 
classification established largely for clinical usage (1982; Cohen 1983). In this 
classification, BL retained the term ”small non-cleaved lymphoma” which was 
introduced in the Lukes and Collins classification. The small non-cleaved lymphoma 
(SNCL) group of the IWF included two main pathological variants: Burkitt’s and non-
Burkitt’s lymphomas. The case was called Burkitt’s type when it satisfied the WHO 
expert committee criteria.  
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1.4.4 Kiel Classification. 
 
The original Kiel classification (Kruger, Grisar et al. 1981) included BL in the general 
B-lymphoblastic category whereas the updated version (Stansfeld, Diebold et al. 
1988) put BL as a morphologically and immunophenotypically distinct entity. No 
changes in the morphologic description of BL were made in this classification.  
 
1.4.5 Revised European American Classification (REAL). 
 
The International Lymphoma Study Group proposed the REAL classification of 
lymphoid malignancies which took into account morphological, immunological, genetic 
and clinical features of malignant lymphoproliferative disorders(Harris, Jaffe et al. 
1994). In this classification, classic BL as well as a provisional entity of Burkitt’s- like 
lymphoma were recognized. The Burkitt’s-like lymphoma category referred to non-
Burkitt’s type, small non-cleaved lymphoma with plasmablastic differentiation. This 
morphologic variant is recognized by its cellular heterogeneity, variation in nuclear 
size and presence of large nucleoli as illustrated in Figure 1.2 (Hui, Feller et al. 1988). 
 
1.4.6 The World Health Organization (WHO) Classification.  
 
The current WHO classification of lymphoid malignancies recognizes classical BL as 
well as BL variants (Harris, Jaffe et al. 2000). The variants include the BL with 
plasmablastic differentiation and atypical Burkitt’s/Burkitt’s-like variant which were 
included as a provisional entity in the REAL classification. The classical BL description 
of small non-cleaved cells has remained unchanged in this classification (Illustrated in 
Panel A of Figure 1.2 ). 
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1.5 Morphologic features of Burkitt’s lymphoma. 
 
As discussed, the main morphologic entities are classic BL, BL with plasmacytoid 
differentiation as well as atypical BL/ Burkitt’s like lymphoma. These variants are 
illustrated in Figure 1.2 and described below.  
 
1.5.1 Classic Burkitt’s lymphoma. 
 
The classic BL is a homogenous proliferation of medium-sized lymphoid cells with 
round, non-cleaved nuclei, multiple centrally located nucleoli and a clumped chromatin 
pattern (Berard 1985; Harris, Jaffe et al. 2000). They have deeply basophilic 
cytoplasm with abundant lipid vacuoles. On histological sections, the cells are 
monomorphic with multiple basophilic nucleoli and show a cohesive growth pattern. 
Histological sections show the typical “starry-sky” appearance due to the presence of 
numerous benign macrophages that have ingested apoptotic tumor cells. The nuclear 
size of the tumour cells is the same as that of admixed starry-sky histiocytes. 
Classical BL morphology is typically observed in the eBL and in a high proportion of 
sBL occurring in children (1969; Harris, Jaffe et al. 2000).  
 
1.5.2 Burkitt’s lymphoma with plasmacytoid differentiation. 
 
Morphologically this variant is comprised of medium-sized cells with eccentric 
basophilic cytoplasm containing lipid vacuoles. The nucleus displays some degree of 
pleomorphism in shape and size and often has a single central nucleus (Harris, Jaffe 
et al. 1994). Plasmacytoid differentiation is more common in immunodeficiency states 
(Hui, Feller et al. 1988). Unlike classic BL which displays some degree of tumor  
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cell homogeneity, plasmacytoid differentiated BL shows tumor size heterogeneity with 
with variation in nuclear size and shape.  
 
1.5.3 Atypical BL/ Burkitt’s-like lymphoma. 
 
This variant comprises medium sized cells with a greater degree of pleomorphism of 
size and shape as compared to the classical BL. Nucleoli are more prominent and 
fewer in number (Felman, Bryon et al. 1985; Harris, Jaffe et al. 1994). The tissue 
histological features are the same as those of classic BL (Raphael, Gentilhomme et 
al. 1991). 
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Figure 1.2    Morphologic variants of BL. Panel A shows the Classic BL morphology, 
Panel B is the plasmacytoid variant of BL and Panel C is Burkitt’s-like variant. Please 
refer to section 1.5 in the text for description of these BL morphologic variants. Panel 
A is patient BL 4, panel B is patient BL12 and Panel C is patient BL 22( Please refer 
to results section, table  4.2 for further details on these patients) 
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1.6 Flow cytometric features of BL. 
 
Surface marker analysis using flow cytometry has revolutionized and enhanced our 
understanding of many lymphoproliferative disorders including BL. Burkitt’s lymphoma 
is now immunophenotypically well described with characteristic light scatter,  
phenotypic expression and DNA Ploidy features. The tumor cells express membrane 
IgM, light chain restriction and B-cell antigens. These immunophenotypic features   
are illustrated in Figures 1.3 and 1.4. In the routine diagnostic setting, these 
immunophenotypic findings are not pathognomic of BL but should always be 
interpreted in the context of the clinical presentation and morphologic findings of the 
patient.  
 
1.6.1 Light scatter analysis. 
 
BL can be identified on forward and side light scatter flow analysis as small to 
intermediate sized cells located in the lymphoid gate. These tumor cells are slightly 
larger and more complex than small mature lymphocytes (Magrath, Pizzo et al. 1980; 
Dive, Gregory et al. 1992; Nelson, Treaba et al. 2006). Burkitt’s lymphoma with a 
leukemic phase may show extension of the tumor cell population towards the blast 
gate reflecting the tumor cell immaturity. This extension is shown in Panel A of Figure 
1.3. 
 
1.6.2 Phenotypic expression. 
 
The postulated cell of origin for BL is the germinal centre B-cell (Hui, Feller et al. 
1988; Jack, Barrans et al. 2005) and therefore BL express BCL-6. The diagnostic 
phenotype of BL has been defined as a combination of CD10 expression in 
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Figure 1.3    Flow cytometry features of BL. 
Panel A shows the light scattergram of a bone marrow analysis with extensive BL 
tumor cells involvement (96%)( indicated by red dots). Note the variable size range of 
the tumor cells and a few residual T-cells shown in green dots. In Panel A there is 
virtually no residual normal haemopoiesis. Panel B is the analysis of a lymph node 
showing CD19 and Kappa light chain co-expression on BL tumor cells (red dots). 
Panel C demonstrates a bone marrow with 30% tumor cell involvement showing 
CD19/CD10 co-expression in blue. The green and grey dots are background T-cells 
and granulocytes respectively.  Panel D shows analysis of a lymph node with BL 
tumor cells (red dots ) with classic kappa light chain restriction. The flow cytometric 
data was acquired using a FACSCalibur flow cytometer with Paint-A-gate software 
(Becton Dickinson, Fullerton, CA, USA) 
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association with pan B-cell markers and light chain restriction. (Hui, Feller et al. 1988; 
Harris, Jaffe et al. 1994). The B-cell markers commonly demonstrable are CD19, 
CD20 and CD22. Burkitt’s lymphoma does not express CD5, CD23 or BCL-2 which 
distinguishes it from Chronic Lymphocytic Leukemia and other NHLs. Expression of 
CD21 has been described  in the endemic form but is largely absent from the sporadic 
cases (Magrath, Janus et al. 1984). Burkitt’s lymphoma typically shows co-expression 
of CD10 and light chain expression. The differential diagnosis for this includes 
Follicular Cell lymphoma, B-Acute Lymphoblastic Lymphoma  and Diffuse Large Cell 
Lymphoma. Ki-67, which is a  cellular activation marker used in histopathology,  is 
usually very high, present in nearly 100% of the BL tumor cells (Hui, Feller et al. 1988; 
Harris, Jaffe et al. 1994). This finding is consistent with the high grade nature of this 
tumor. 
 
1.6.3 DNA Ploidy analysis. 
 
In Burkitt’s lymphoma, most of the tumor cells are active in cell cycle. It is therefore 
not surprising that the S-phase fraction is almost invariably very high, typically in the 
region of 20-40% (Christensson, Lindemalm et al. 1989; Pinto, Cabecadas et al. 
2003). This feature is often critical in distinguishing this lymphoma from other high 
grade lymphomas such as Diffuse Large cell lymphoma which usually have low S-
phase fractions (Pinto, Cabecadas et al. 2003). Most of the BL cells are diploid in 
chromosome composition although occasional aneuploid forms are seen (Wilson, 
Mian et al. 1987; Nelson, Treaba et al. 2006; Wu, Borowitz et al. 2006). An example of 
classic BL with high S-phase fraction and aneuploid DNA composition is shown in 
figure 1.4 below.  
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1.7 Genetic and molecular features of BL. 
1.7.1 Chromosomal abnormalities in BL. 
All the clinico-epidemiological variants of BL, including the eBL, sBL, AIDS-BL and 
ALL L3 share a common genetic background. They are characterized by balanced 
chromosomal translocations involving the c-myc gene locus and one of the 
immunoglobulin chain loci. In 80% of BL, the translocation partner of c-myc is the 
immunoglobulin heavy chain (IgH) giving rise to the t(8;14)(q24;q32) translocation 
(Lai, Fenaux et al. 1989; Harris, Jaffe et al. 1994; Dave, Fu et al. 2006). The 
remaining 20% of BL involve c-myc and either the kappa light chain locus (in 15% of 
cases) or the lambda light chain locus (5%) (Bernheim, Berger et al. 1981) giving rise 
to the t(2;8)(q12;q24) and t(8;22)(q24;q11) variant translocations. The presence of 
t(8;14) or its variants are very useful in supporting a diagnosis of BL but are thought to 
be very poor predictors of disease outcome on their own (Glassman, Hopwood et al. 
2000). It is only when these aberrations occur in the context of other additional 
chromosomal abnormalities that they are predictive of poor outcome (Glassman, 
Hopwood et al. 2000; Lones, Sanger et al. 2004). 
 
Cytogenetic analysis is hampered in about 10% to 20% of the general specimens by a 
low mitotic index or poor quality of metaphase spread (Offit, Jhanwar et al. 1991; 
Siebert, Matthiesen et al. 1998). The scattering of breakpoints on 8q32 and 14q32 
necessitates the use of multiple probes and sequence specific primers which render 
techniques such as Southern blotting time consuming and difficult to implement for  
routine diagnosis. FISH overcomes certain limitations posed by cytogenetics and 
molecular analysis and enables detection of chromosomal abnormalities independent 
of cycle status of the cells.  
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To detect chromosomal breakpoints by FISH, various  approaches have been 
reported including the use of 1)chromosome library probes, 2) YACs, 3) chromosome 
specific centromeric probes and 4) coloured cosmid probes flanking the potential 
breakpoint(Lishner, Kenet et al. 1993; Tbakhi, Pettay et al. 1998; Glassman, Hopwood 
et al. 2000; Zunino, Viaggi et al. 2000; Szeles 2002).  
 
 
Figure 1.4   Burkitt’s lymphoma DNA ploidy analysis. Panel A is a classic example of 
BL DNA ploidy with high S-phase fraction of 35% shown by the arrow. The first peak 
on the right in Panel A represents the diploid chromosome complement and the 
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second smaller peak is an aneuploid population. Panel B is normal Diploid DNA with 
no increase in S-phase or aneuploid DNA. 
 
 
 
 
 
Figure 1.5   FISH analysis of the t(8;14) translocation in BL.  The green signal ( arrow 
1) shows hybridization to the IgH gene. The red signal indicates hybridization to the 
myc gene( Arrow 2). The t(8;14) is represented by the joining of the two signals 
(yellow) as shown in the two arrows labeled 3. The presence of the two colocalizing 
signals are in keeping with the reciprocal translocation seen in BL ( Picture courtesy of 
the NHLS Molecular Cytogenetics unit). 
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This is illustrated in Figure 1.5 which shows FISH analysis for the detection of the 
t(8;14) translocation using two different cosmid probes, one specific for the IgH gene 
and the other for the c-myc gene. The t(8;14)  translocation is shown by the composite 
signal designated  by a yellow colour and arrow numbered 3.  
 
1.7.2 The pathology of t(8;14) translocation. 
 
As discussed, this cytogenetic lesion was first described in 1972 and was the first 
translocation to be non-randomly associated with a lymphoid malignancy in 1976 
(Manolov and Manolova 1972; Zech, Haglund et al. 1976). Figures 1.1 and 1.6 are 
schematic representations of the t (8;14) translocation. It is a balanced translocation 
mediated by recombinase enzymes in which the q24 locus on chromosome 8 is 
relocated to the long arm of chromosome 14 and the q32 locus on 14 is moved to the 
long arm of chromosome 8.  
 
DNA sequence analyses have provided some insight into the timing and mechanism 
of the translocation event in the various subtypes of BL.  In sBL and AIDS-BL with the  
t(8;14) translocation, the positions of the breakpoints in chromosome 14 suggest that 
they were created during attempted immunoglobulin class switching. This event is 
usually confined to germinal centre B cells, providing further support for a germinal 
centre B-cell origin of these forms of BL (Kaiser-McCaw, Epstein et al. 1977; Hecht 
and Aster 2000). In contrast, for eBL associated with t(8;14), the JH segments  
flanking the breakpoints usually have deletions and/or additions of base pairs that are 
characteristic of normal Ig VDJ segment rearrangement (Haluska and Croce 1987; 
Haluska, Tsujimoto et al. 1989). 
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Several models are plausible for the timing of t(8;14) formation in eBL. The re-
arrangement of c-myc is an early event occurring in pre-B cells at the time of 
attempted VDJ recombination. The B cells then undergo maturation to germinal center 
cells and acquires additional genetic aberrations that collaborate to produce 
BL(Hikida, Mori et al. 1996; Han, Huang et al. 2006). In a second model, re-
expression of RAG1 and RAG2 in germinal centres reactivates VDJ recombination 
and permits the t(8;14) to occur at this later stage of B-cell differentiation (Ma, Fisher 
et al. 1992; Ma, Pannicke et al. 2002; Raghavan, Swanson et al. 2005; Zou, Ma et al. 
2007). 
  
Very little is known about the mechanisms causing chromosomal breaks in c-myc. 
The breakpoints in c-myc occur in sites with no homology to VDJ recombination which 
suggest that they are unlikely to be dependent upon these activities(Gao, Smith et al. 
1997). 
 
Junctional sequences created by the t(8;14) translocation are in divergent orientation 
with the 5’  end of the c-myc gene juxtaposed to the 5’ end of the IgH gene (Basso, 
Frascella et al. 1999). As a consequence of this opposite orientation of the genes, no 
resultant functional fusion gene is formed. However, the functional consequence of 
the t (8;14) is a positioning of Ig enhancers in close proximity to the c-myc gene 
resulting in c-myc transcriptional dysregulation and consequent c-myc mRNA and 
protein overexpression.  In addition, the regulatory sequences residing within c-myc 
are removed or mutated during the translocation resulting in increased c-myc activity 
(Hecht and Aster 2000). The mutated c-myc gene alters the amino acid sequence of 
the c-myc protein and this change can be detected by western blotting. The relative 
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positions of the breakpoints in the c-myc gene on chromosome 8 and IgH on 
chromosome 14 appear to result in the different phenotypes of the BL variants  
 
 
 
μ μ ααγ γσμ
μ μ ααγ γσμ
 
 
 
Figure 1.6   Schematic representation of the t(8;14) translocation. The breakpoints in 
the MYC gene usually occur at exon 1or intron 1 whilst those in the IgH gene are 
variable and could occur in the JH gene, switch regions or constant regions. The 
t(8;14) result in the 5’-5’ orientation of the MYC and IgH gene segments with the 
consequent dysfunctional DNA segment (Pelicci, Knowles et al. 1986; Gutierrez, 
Bhatia et al. 1992).  
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In the eBL, the breakpoints on chromosome 8 occur more than 100kb 5’ to the c-myc 
exon 1.. IgH breakpoint on chromosome 14 is within the joining region. These 
breakpoints seem to occur during the attempted VDJ recombination process critical to 
immunoglobulin rearrangement during B cell development.  In the eBL, c-myc 
transcription is driven by the normal P1 and P2 c-myc enhancers. In the sBL and  
AIDS-BL the chromosome 8 breakpoints are between c-myc exon 1 and 2 and within 
the switch region on chromosome 14, resulting in a different molecular rearrangement 
and therefore different BL phenotypes 
 
The breakpoint in the IgH gene occurs during attempted immunoglobulin switching. 
The translocation results in the loss of c-myc exon 1 and P1 and P2 promoters. C-myc 
transcription occurs from a cryptic promoter. In the BL variant translocations, the 
breakpoints on chromosome 8 are located 3’ to the c-myc gene. The chromosome 2 
and 22 breakpoints occur 5’ to the kappa and lambda genes respectively (Neri, 
Barriga et al. 1988; Shiramizu, Barriga et al. 1991; Joos, Falk et al. 1992; Joos, 
Haluska et al. 1992) 
 
The breakpoints characteristic of the different BL variants are shown by arrows on 
chromosomes 8 and 14 in Figure 1.7. The symbols Cµ, Sµ and Eµ represent the 
constant, switch and enhancer regions of the immunoglobulin heavy chain. The 
variable, diversity and joining regions of the immunoglobulin heavy chains are 
represented by V, D and J respectively. The BL variants are represented by sBL, eBL 
and HIV BL for sporadic, endemic and AIDS related BL respectively.  
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Figure 1.7   Schematic representation of the translocation breakpoints in BL. In sBL 
and HIV-BL the breakpoints on chromosome 8 are within intron 1. In eBL breakpoints 
occur 5’ to the c-myc gene. On chromosome 14, the breakpoints are in the Sµ region 
with sBL and HIV-BL and in the J region with the eBL ( Illustration from Blum et al 
2004). 
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. 
1.7.3 The biological consequences of c-myc dysregulation. 
 
c-Myc plays a central role in a number of cellular processes. It appears to enhance 
apoptosis, cell cycle progression and telomerase activity (Marcu, Bossone et al. 1992; 
Mateyak, Obaya et al. 1999). c-Myc downregulates differentiation and cell adhesion 
(Langdon, Harris et al. 1986; Felsher and Bishop 1999; Felsher and Bishop 1999). 
The net c-myc effect of myc over expression is uncontrolled cell proliferation with 
associated genomic instability and cell immortalization. These findings have been 
summarized graphically in figure 1.8. 
 
1.7.4 Clonality and immunoglobulin analysis in BL 
 
The distinction between neoplastic and reactive disorders in the diagnosis of 
lymphomas still presents a challenge to pathologists. In many instances the 
combination of morphology and immunophenotype findings can be difficult to interpret 
(Delecluse, Raphael et al. 1993; Fodinger, Winkler et al. 1999). Demonstrating 
clonality by the detection of rearrangement of the immunoglobulin (Ig)  gene provides 
a strong argument for differentiating neoplastic from reactive lymphoproliferative 
disorders(Hecht and Kaiser-McCaw 1981; Hecht and Aster 2000).  
 
During B-cell ontogeny,  a  series of double stranded DNA breaks occur to produce a 
functional Ig gene(Vanasse, Concannon et al. 1999; Willis and Dyer 2000). Errors 
occurring during these events as well as defects in other DNA repair genes may 
predispose B-cells to Ig loci translocations associated with certain specific lymphoid 
neoplasms. The principal consequences of Ig translocations are deregulated 
  
  30 
 
expression and in some instances, mutation of the translocated genes.  Therefore 
studying immunoglobulin gene rearrangement can be  an important tool for studying 
 
 
 
 
Figure 1.8   Cell biological consequences of c-MYC.  (Modified from Blum et al 2004)  
 
 
  
  31 
 
 
B-cell clonality.  In the case of BL, demonstration of clonal Ig gene rearrangement or 
light chain restriction by flow cytometric analysis is an important step in confirming 
clonality.  
 
Southern blotting is the established method detecting Ig gene rearrangement. The 
limitations of this technique are it’s poor sensitivity and being time consuming and 
labour intensive. Clonality analysis of lymphoid cells using PCR to amplify the VDJ 
Junctional region of the Ig heavy chain gene can circumvent some of the 
disadvantages of the Southern blotting. Experience with application of PCR for Ig 
heavy gene rearrangement has been limited owing to the limitation of the spread of 
the breakpoints involved in BL translocations (Akasaka, Muramatsu et al. 1996; 
Armes, Southey et al. 1996).  
  
1.7.5 Microarray analysis in Burkitt’s lymphoma.  
 
Molecular analysis of BL has recently been enhanced by the availability and 
application of microarray technology to lymphoma diagnosis. Although experience 
with BL gene expression profiling is still limited, recently published studies suggest 
that microarray technology using the BL molecular signature is potentially superior to 
morphology, cytogenetics and immunophenotypic analysis at accurately identifying 
and differentiating BL from other categories of  diffuse large cell lymphomas. (Dave, 
Fu et al. 2006; Hummel, Bentink et al. 2006). This molecular classification is able to 
identify the morphologically classical as well as atypical forms of BL (Hummel, Bentink 
et al. 2006).  
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It is now widely accepted that correct identification of BL with atypical morphology is 
particularly challenging in the background of HIV infection (Diebold, Raphael et al. 
1997; Cabalo, Wilkinson et al. 2002; Cheung 2004). Although there are no studies 
done on HIV infected patients as yet, the BL molecular signature used in microarray 
analysis is unlikely to be affected by HIV infection and may prove to be a useful tool in 
addressing this diagnostic dilemma.  
 
The BL molecular signature also allows identification of a subset of this BL tumour 
without FISH or karyotype demonstrabl immunoglobulin-myc BL translocation (Dave, 
Fu et al. 2006). Using currently available non-microarray diagnostic tools, these 
lymphomas would have been misclassified and mismanaged as non-Burkitt’s 
lymphomas.  
 
One of the critical advances of this type of molecular classification is its ability to 
accurately differentiate BL from Diffuse Large Cell Lymphomas (DLCL) where  
morphological features may be identical (Hummel, Bentink et al. 2006). Burkitt’s 
lymphoma and DLCL require different therapeutic approaches necessitating correct 
identification of these lymphomas. In a recent microarray analysis of lymphomas, a 
number of morphologically characterized DLCLs had the typical gene-expression 
profile of BL (Dave, Fu et al. 2006)   
 
Lymphomas with morphologic features that are intermediate between those of BL and 
Diffuse Large Cell Lymphoma have been termed non-Burkitt or Burkitt-like 
lymphomas. In the WHO classification Burkitt-like lymphoma is reserved for those 
entities with immunophenotypic and genetic criteria charactericstic of BL with atypical 
morphologic features (Harris, Jaffe et al. 2000; Harris and Horning 2006). Preliminary 
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data suggest that it would be possible to accurately classify these atypical BL using 
gene expression profiling (Hummel, Bentink et al. 2006). 
 
EBV specific microarray chips have also become recently available (Gomez-Curet, 
Perkins et al. 2006; Hummel, Bentink et al. 2006; Li, Chen et al. 2006). EBV 
microarray analysis is likely to enhance our understanding of the role this virus plays 
in the aetiology, pathogenesis and prognosis of BL and it’s subtypes..  
 
The great impact of microarray analysis in BL is thus likely to be its use as a 
diagnostic tool to determine the type of therapeutic intervention required to treat the 
lymphoma.  There is already evidence to indicate that patients with a molecular 
diagnosis of BL who are treated with aggressive chemotherapeutic regimens have 
better outcomes than those who received standard chemotherapy (Dave, Fu et al. 
2006). 
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CHAPTER  2 
2.0 DIAGNOSTIC CHALLENGES IN BURKITT’S LYMPHOMA. 
2.1 Clinical diagnostic challenges in BL. 
 
The three clinical variants of BL described in the previous chapter would appear to be 
fairly distinct clinico-epidemiological entities. However, there is some considerable 
overlap in their clinical features and epidemiological characteristics(Blum, Lozanski et 
al. 2004).   
Although jaw mass presentation is very characteristic of eBL, occurring in up to 72% 
in some eBL series (Wang, Strasnick et al. 1992; Carbone, Canzonieri et al. 2000; 
Mwanda, Orem et al. 2005), it is not exclusive to endemic areas. Jaw mass 
presentation of sBL and AIDS-BL occur frequently outside the BL endemic areas. 
These clinical presentations have been extensively reported both as case studies and 
case series (Mukerji and Hilfer 1993; Jan, Vora et al. 2005; Ugar, Bozkaya et al. 
2006). In the Muwakkit sBL series, 17% of cases presented with jaw masses 
(Muwakkit, Razzouk et al. 2004) which is high for this study done in a non-endemic 
region.  
 
This clinical resemblance of eBL by sBL and AIDS-BL may be partly a consequence 
of population migrations and blurring of boundaries between endemic and non-
endemic geographic locations. This has significantly reduced the clinical utility of jaw 
mass presentation in differentiating the various clinico-epidemiological variants. It is 
quite clear therefore, that neither the geographic location of the patient nor the 
anatomic location of the tumor are reliable clinical indicators for differentiating the eBL 
from the sBL.  
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It is now well established that HIV infection mimics and often masks the classical 
clinical features of many diseases, including lymphomas (Whitworth, Birchall et al. 
1993; Clunie and Macleish 1994; Druillennec, Dong et al. 1999). A patient with BL and 
persistent generalized lymphadenopathy or lymphadenopathy secondary to infection  
may be clinically indistinguishable from a lymphoma with nodal presentation (Tirelli, 
Vaccher et al. 1987; Zagonel, Tirelli et al. 1988; Tirelli, Vaccher et al. 1989; Aguilar 
Ligorit, Guix Garcia et al. 1990; Peter, Boyle et al. 1994; Bhargava, Chang et al. 
2006). Distinguishing AIDS-related BL from infections or other lymphomas in the 
setting of HIV remains a challenge which can lead to incorrect diagnostic evaluation 
and therapeutic interventions.  
 
2.2 Morphological diagnostic challenges in BL. 
 
Although BL cytomorphology suggests a single homogenous entity, there is a 
significant degree of tumor morphological variation occurring as a result of intrinsic 
and extrinsic factors.  
Intrinsic nuclear pleomorphism is well described in BL and is characteristic of the 
Plasmacytoid differentiated and atypical/Burkitt’s-like variants (Harris, Jaffe et al. 
1994; Harris, Jaffe et al. 2000). In the absence of extrinsic modifying factors, extreme 
nuclear pleomorphism is associated with atypical BL whilst mild to moderate 
pleomorphism is characteristic of the plasmacytoid morphologic variant.   
 
Burkitt’s lymphoma morphology is often poorly discernable in the setting of extrinsic 
factors such as infections, drugs, toxins and concomitant other pathology. HIV 
infection is frequently associated with  dysplastic cytomorphologic changes which are 
known to complicate diagnostic assessments (Marche, Tabbara et al. 1990; Sham 
and Bennett 1992). Significant dysplasia is also associated with exposure to a number 
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of toxins and drugs. The classic examples are steroids and chemotherapeutic agents 
which are also important in the therapeutic management of lymphomas (Irvine, Magill 
et al. 1998). Morphologic differentiation of the various BL variants is often very 
challenging even in the hands of skilled morphologists. Therefore, establishing a 
definitive morphological diagnosis of BL in the presence of these factors is often 
challenging and sometimes impossible.      
Morphologic differentiation of leukemic BL from Acute Lymphoblastic Leukemia L3 
subtype poses a special challenge. Distinct management protocols dictate that these 
entities be differentiated. Morphologic features, age of presentation,  and sites of 
involvement of these two diseases are often indistinguishable (Sham and Bennett 
1992; Velangi, Reid et al. 2002). Distinction between them is ultimately reliant on flow 
cytometry, cytogenetics and molecular analyses (Harris, Jaffe et al. 2000).                                         
 
2.3 Cytogenetic diagnostic challenges in BL. 
 
Traditional karyotypic analysis is unsuccessful in approximately 10-20% of blood and 
bone marrow specimens due to a low mitotic index of cells or poor quality of the 
metaphase spread (Offit and Chaganti 1991; Offit, Jhanwar et al. 1991; Offit, Wong et 
al. 1991; Siebert, Matthiesen et al. 1998). In BL, which is a high grade lymphoma  the 
cytogenetic yield is expected to be significantly better. However, there is currently no 
published data to support this expectation.  
 
The second limitation of conventional cytogenetics for the analysis of BL is the 
requirement for fresh, viable cellular specimens. Archival material and old specimens 
are unsuitable for analysis by this technique. In recent studies, cytogenetic variants 
such as fluorescence in-situ hybridization (FISH) have been shown to be suitable 
alternatives (Siebert, Matthiesen et al. 1998). 
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2.4 Southern blot analysis in BL. 
 
Southern analysis was the first molecular tool used to elucidate the molecular 
pathology of many haematologic malignancies including the translocations in BL 
(Bernard, Cory et al. 1983). Until recently, it has been considered the gold standard in 
BL molecular analysis (Vital, Merlio et al. 1992). Although the impact of using this 
technique was significant in our early understanding of the BL molecular 
pathophysiology, it has a number of disadvantages which make it unsuitable for 
routine diagnostic use. These  include the extremely slow turnaround times, high level 
of technical expertise required,  exposure to radioactivity, very low sensitivity and the 
need to use multiple probes which increases the cost significantly (Langerak, 
Szczepanski et al. 1997). Consequently, southern blotting has been largely replaced 
by the cheaper, faster and sensitive polymerase chain reaction (PCR) approaches.  
 
2.5 Polymerase chain reaction (PCR) analysis in BL.  
 
Since its invention, PCR has become the molecular tool of choice for diagnostic 
investigation, detection of prognostic markers, disease monitoring and minimal 
residual disease detection of many haematological malignancies and infections. PCR 
is highly sensitive with fast turnaround times making it suitable for routine diagnostic 
applications (Buchbinder, Josephs et al. 1988; Lo and Chan 2006; Rumsby 2006).   
 
Whilst PCR is currently extensively used in the routine diagnosis of many  
lymphoproliferative disorders (Williams, Zukerberg et al. 1995; Au, Horsman et al. 
2002; Jiang, Medeiros et al. 2002; Janz 2006; Lo and Chan 2006; Rumsby 2006), it 
has not been readily available for routine detection of translocations in BL for two 
reasons. Firstly, BL is very heterogeneous at a molecular level, breakpoints in the    
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t(8;14) translocation are distributed over a large region yielding products that are too 
large to  a synthesize  by standard Taq DNA polymerase amplification. The standard 
Taq polymerase can only amplify targets up to 3 kilobases long (Akasaka, Muramatsu 
et al. 1996). Secondly, the  breakpoints within the IgH gene sometimes occur within 
the switch region made up of repeat sequences for which unique primers are often 
difficult to design (Blum, Lozanski et al. 2004; Ferry 2006).  
 
2.6 Long distance polymerase chain reaction (LD PCR). 
 
Recently, the DNA polymerases have been improved for effective amplification of 
longer targets from human genomic DNA. These polymerase improvements and 
optimization were first described by Cheng and colleagues in 1994 (Cheng, Fockler et 
al. 1994). The DNA polymerases used in LD-PCR have identical thermostable and 
polymerase  properties as the standard Taq DNA polymerase. They differ from Taq by 
possessing the 3’-5’ exonuclease or “proof reading” activity. The exonuclease activity 
prevents mis-incorporation of nucleotides and therefore improves the efficacy of long 
segment amplification.  
 
Since the original description, a number of these DNA polymerases with exonuclease 
activity have been described, optimized and commercialized. These  include the 
Pwo/Taq DNA polymerase mixture supplied by Boerhinger Mannheim (Hinnisdaels, 
Del-Favero et al. 1996) and Tgo/Taq DNA polymerase enzymes mix supplied by 
Roche (Hopfner, Eichinger et al. 1999). Optimization of these polymerase mixtures 
has been accomplished by increasing the pH, adding glycerol and dimethysulphoxide 
(DMSO), decreasing denaturation times and increasing the extension time. Under 
these optimized conditions, they are capable of synthesizing DNA fragments up to 
23Kb long (Cheng, Chang et al. 1994; Cheng, Fockler et al. 1994).  
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Preliminary studies suggest that the LD-PCR enzyme mixture can be used for the 
detection of translocations in a variety of B-cell lymphoproliferative disorders(Akasaka, 
Muramatsu et al. 1996; Akasaka, Ohno et al. 1997). In these settings, LD-PCR has 
been shown to be highly sensitive, with a detection limit of 1 in 1000 malignant cells 
with ethidium bromide staining and 1 in 10 000 with radioactive detection. These data 
suggest that LD-PCR is a sensitive technique suitable for minimal residual disease 
detection. 
 
 The specific application of the optimized LD-PCR in the detection of the t(8;14) 
translocation in BL suggests that it is fast, highly sensitive and specific (Akasaka, 
Ohno et al. 1997; zur Stadt, Reiter et al. 1997; Basso, Frascella et al. 1999; Mussolin, 
Basso et al. 2003). There are currently three published studies on the utility of LD 
PCR for the diagnosis of BL and findings have been summarized in Table 2.1 below. 
 
Table 2.1   Summary of published LD-PCR studies in BL. 
Publication Number of BL analyzed 
Source of 
DNA 
Age of 
patients 
Proportion 
diagnosed 
with LD_PCR 
Zur Stadt et al 
1999 20 Bone marrow Pediatric 11/20(55%) 
Basso et al 
1999 15 Bone marrow Pediatric 13/15(87%) 
Mussolin et al 
2003 78 Bone marrow Pediatric 52/78(67%) 
   
These studies have been conducted entirely in the paediatric age group in the setting 
largely of sBL. To date, no LD-PCR analysis of adult patients, patients with eBL or 
AIDS-BL have been published. All studies have been done on bone marrow aspirate 
and biopsy specimens and there was bone marrow involvement in all cases included. 
The proportion of known BL identified by LD-PCR was variable, ranging from 55-87%.  
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Despite the specificity and sensitivity of t(8;14) translocation PCR, it is noteworthy that 
this cytogenetic lesion could not be demonstrated in a significant number of known BL 
cases. Theoretically, the reasons for these are numerous and would include the 
variant of BL studied, the specificities and number of primers used in the PCR 
analysis and extent of bone marrow involvement. 
  
2.7 Rationale for the current study. 
 
The HIV pandemic has had its greatest effect in sub-Saharan Africa, but there is little 
published data available to support an increase in NHL in the region. The projected 
frequency of NHLs is expected to increase even further as the life expectancy of HIV-
infected individuals is prolonged by novel antiretroviral therapeutic strategies (Pluda 
and Yarchoan 1990; Pluda, Yarchoan et al. 1990; Beral, Peterman et al. 1991).  
 
The two common AIDS-related NHLs are BL and diffuse large cell lymphoma (DLCL) 
of B-cell origin. It is pertinent to distinguish these NHL as patient management 
approaches and treatment outcomes differ significantly.(Lim, Karim et al. 2005).  For 
example, Burkitt’s lymphoma, as opposed to DLCL, frequently presents with 
extranodal disease, with CNS involvement requiring intense, aggressive 
chemotherapy including intrathecal treatment. Upto 30% of cases of DLCL show 3q27 
region abnormalities and 20-30% have translocation of the BCL2 gene ( Harris, Jaffe 
et at 2000). 
 
In the setting of HIV, morphological distinction between these two NHL can be very 
challenging.  The hallmark of BL and important distinguishing feature is the associated 
t(8;14) translocation seen in the majority of individuals with this neoplasm. Diffuse 
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large cell lymphoma is not associated with a specific recurrent chromosomal 
translocation. 
 
Although the t(8;14) translocation was the first non-random abnormality to be 
described in lymphoid malignancies and occurs in 80% of BL, it has not been possible 
to use this as a diagnostic tool for BL prior to introduction of LD-PCR technique. The 
recent availability of this technique has made it possible to characterize BL in our 
setting which is unique in several ways. Johannesburg is a cosmopolitan city which is 
often the first port of call for African migrants seeking medical attention. Although the 
predominant BL epidemiologic variant in South Africa should be sBL, this has been 
significantly altered by perennial population migrations from central and west Africa to 
Johannesburg. When this migration mix is superimposed on the current HIV epidemic, 
all three BL subtypes would theoretically be expected in Johannesburg. There are 
currently no studies done to characterize the clinico-epidemiology of BL in this region.  
 
Previous molecular studies have demonstrated that the t(8;14) translocation 
breakpoints  occur at different sites in the eBL and sBL (Pelicci, Knowles et al. 1986). 
As illustrated in Figure 1, the breakpoints in sBL and AID-BL are clustered within the 
first intron whereas in eBL they occur 5’ to the first exon on chromosome 8. On 
chromosome 14, the eBL breakpoints are found in the joining region and those for the 
sBL and AIDS-BL are located in the switch region of the IgH. With the t(8;14) 
translocation LD-PCR, it is possible to characterize the various BL variants based on 
the PCR product size. This molecular analysis of BL subtypes has not yet done 
across all age groups in our cosmopolitan population with high HIV prevalence. 
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2.9 Aims of the current study. 
 
The aims of this study are  
 
• To establish and optimize the LD-PCR assay for the t(8;14) translocation using  
well characterized BL cell lines 
• To apply this LD-PCR technique to retrospectively analyze the t(8;14) 
translocation  in adult and pediatric Burkitt’s lymphomas previously diagnosed 
in Johannesburg during a ten year period from January 1994 to December 
2003. 
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CHAPTER  3 
3.0 MATERIALS AND METHODS. 
3.1 Selection of patients for the study. 
 
Subjects for this study were paediatric and adult patients with a diagnosis of Burkitt’s 
lymphoma made at the academic teaching hospitals affiliated to the University of the 
Witwatersrand, Johannesburg. These hospitals included the Johannesburg Hospital, 
Chris Hani Baragwanath Hospital and the Helen Joseph Hospital.  The diagnosis was 
made by the treating doctors on the basis of a combination of clinical, morphological, 
cytogenetic and flow cytometric criteria. The diagnostic criteria are well established  
and some of them are summarized in Table 3.1 below (Harris 1967; Magrath 1991; 
Harris, Jaffe et al. 1994; Harris, Jaffe et al. 2000; Mwanda 2004; Haralambieva, 
Boerma et al. 2005).  
 
Only subjects with an established and confirmed diagnosis of BL with bone marrow 
involvement were considered for inclusion in this study.  Subjects with ALL-L3 were 
carefully identified by morphology, flow cytometry and clinical features and not 
considered for the study. Those patients with a diagnosis of BL made on tissue biopsy 
without bone marrow involvement or tissue cells available for flow cytometric analysis 
were also identified and excluded.   
 
In this retrospective analysis, any patient with a diagnosis of BL but no bone marrow 
material left from the routine diagnostic procedure were not included in the study. 
There was no bone marrow procedure done specifically to obtain material for this 
research. 
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Table 3.1   Criteria for diagnosis of Burkitt’s lymphoma† 
DIAGNOSTIC CATEGORY DIAGNOSTIC FEATURES  
Clinical features  
• B-symptoms 
• Tumor mass (Jaw, abdominal etc) 
• Organomegaly ( spleen ,liver etc) 
• Clinical features of bone marrow failure 
• Organ failure secondary to tumor lysis 
• CNS symptomatology 
 
Bone Marrow Aspirate or 
Peripheral blood 
Morphological features 
• Abnormal lymphoid infiltrate/lymphoid blasts 
• Typical/atypical L3 morphology 
• Displacement of normal haemopoiesis  
Tissue histology features 
(Trephine biopsy , lymph 
node , mass biopsy ) 
• Medium size lymphoid haemopoietic infiltrate 
• Starry sky appearance 
• Displacement / disruption of normal structure 
Flow cytometric 
immunophenotypic features 
• Abnormal lymphoid infiltrate 
• Light chain restriction 
• Pan B cell marker expression 
• High S-phase fraction on DNA Ploidy analysis 
• Aneuploidy 
• Aberrant markers  
 
Cytogenetics features 
• t(8;14) translocation 
• t(8;22) translocation 
• t(2;8) translocation 
• Other cytogenetic abnormalities 
 
† Modified and expanded from the WHO Classification of haematolymphoid 
malignancies (Harris, Jaffe et al. 2000) 
 
3.2 Patient DNA material.  
 
Tissue available for analysis included the following:  
• bone marrow aspirate smears,  
• trephine imprint smears,  
• cell suspensions remaining after the aspirate sample was used for flow 
cytometric analysis.  
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The aspirate and trephine imprint slides were the unfixed archival excess remaining 
after the initial diagnostic workup. Although theoretically there should be no difference 
between the use of stained or unstained slides (Anderegg, Schluter et al. 1998), only 
unstained slides were used as patient DNA source in this research. These slides were 
stored at ambient laboratory temperature (22°C) for varying time periods ranging from 
two weeks to 10 years prior to use in the study. Cells remaining after routine flow 
cytometric analysis were also stored at -20°C for varying periods prior to use.   
 
3.3 Human ethic clearance. 
 
Permission to use patient material for this study was sought from the institutional 
protocol review committee prior to study initiation. Ethics approval was granted by the 
University of the Witwatersrand Human Research Ethics Committee, clearance 
certificate number M00/05/12, which is included as appendix A of this thesis 
 
3.4 Control DNA material. 
 
Positive and negative controls were included with each patient PCR analysis 
performed for the t(8;14) translocation.  Control DNA was extracted from well 
characterized human Burkitt’s’ lymphoma cell lines obtained from the American Type 
Culture Collection (ATCC, Maryland, United States of America).  
 
The t(8;14) translocation positive Burkitt’s lymphoma cell line used was the ATCC 
CA46 repository  originally described by Magrath and colleagues in 1980 (Magrath, 
Lee et al. 1980). It is a human derived cell line obtained from a patient with Burkitt’s 
lymphoma. This cell line had retained its original characteristics with serial 
propagation in culture.  
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The DAUDI cell line DNA, derived from the Burkitt’s lymphoma tumor without t(8;14), 
translocation was used as the negative control. The DAUDI line was the derivative of 
that originally described by Klein and Klein in 1968 (Klein and Klein 1968).  
 
Table 3.2 below describes some of the pertinent features of the DAUDI and CA46 cell 
lines. Both control cell lines were supplied as lyophilized pellets requiring suspension 
and tissue culture propagation prior to DNA extraction.  
 
3.5 Culture of the cell lines. 
3.5.1 Cell culture. 
 
The lyophilized and frozen cell lines were received in sealed sterile ampoules. They 
were rapidly thawed for 60 seconds in a 37ºC waterbath and subsequently immersed 
in 70% ethanol. The entire ampoule volume of 1ml containing 6.8x106 cells was 
suspended in 10ml of freshly prepared RPMI 1640 culture medium (Highveld 
biologicals, South Africa) containing 20% fetal calf serum (FCS, Highveld Biologicals, 
South Africa), 100µg/ml Penicillin G (Novo Nordisk, SA)), 100µg/ml 
Streptomycin,Novo Nordisk, SA) and 100µg/ml Fungizone (Brystol-Meyers-Squib, SA) 
as previously described(Perlman 1979; Prockop 1997). 
 
The culture medium was renewed by washing cells in fresh RPMI within the first 12 
hours of initial culture to remove the cryoprotective dimethy sulphoxide (DMSO). In 
subsequent cultures, cells were seeded at a density of 5x106 cells /ml of RPMI 1640 
culture medium and the growth medium was renewed every 2-3 days or sooner if the 
cell growth was too rapid. Standard aseptic culture techniques were observed and any 
contaminated cultures were immediately discarded and the culture process re-initiated 
from clean stock. 
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Table 3.2   Summary of pertinent features of control BL cell lines† 
 
DESCRIPTION 
 
CA-46 cell line 
 
DAUDI cell line 
ATCC number CRL 1648 CCL0213 
Source Organism Homo sapiens Homo sapiens 
Depositor IT Magrath G Klein 
Tissue Burkitt’s lymphoma Burkitt’s lymphoma 
Receptors expressed Complement (12%) Complement, Fc of IgG 
Morphology Lymphoblast Lymphoblast 
Source 
Organ type: peripheral blood 
Cell type: B lymphocyte 
Disease: Burkitt’s lymphoma 
Organ: peripheral blood 
Cell type: B lymphoblast 
Disease: Burkitt’s lymphoma 
Karyotype 
46,XY, dup1(q21-32), t(8;14) 
(8pter --> 8q23 :: 14q32 --> 
14qter;14pter -->14q32: 8q23 
--> 8qter), 13q+, +16 
Normal male  
Propagation 
ATCC propagation medium: 
RPMI 1640 medium with 2 
mM L-glutamine adjusted to 
contain 1.5 g/L sodium 
bicarbonate, 4.5 g/L glucose, 
10 mM HEPES, and 1.0 mM 
sodium pyruvate, fetal bovine 
serum, 20% 
Temperature: 37.0°C  
Atmosphere: air, 95%; 
carbon dioxide (CO2), 5% 
ATCC propagation 
medium:  RPMI 1640 
medium with 2 mM L-
glutamine adjusted to 
contain 1.5 g/L sodium 
bicarbonate, 4.5 g/L glucose, 
10 mM HEPES, and 1.0 mM 
sodium pyruvate, fetal 
bovine serum, 10% 
Temperature: 37.0°C 
Atmosphere: air, 95%; 
carbon dioxide (CO2), 5% 
 
†Information extracted from the ATCC cell line catalogue( ATCC, Maryland, USA) 
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3.5.2 Cell counting and viability check. 
Five microliters of the cultured cell suspension was diluted 1 in 20 in Turk’s white cell 
counting fluid containing 1% v/v Glacial acetic acid and 0.5% Gentian blue in distilled 
water (Rebulla and Dzik 1994).  
Suspended cells were counted using standard procedure on the Neubauer counting 
haemocytometer with improved rulings (VWP Scientific, Philadelphia, PA, USA).  Cell 
viability was expressed as percentage of live cells to sum total of dead and alive cells. 
Cultures with viability of more than 80% were deemed suitable for subsequent 
subculturing and for use as source control DNA. 
 
3.5.3 Cell harvesting and storage of cultured cells. 
 
A cryopreservation solution containing 10% DMSO in neat Fetal calf serum(FCS) was 
prepared using an aseptic technique. The stock culture cells were counted and then 
suspended in this solution at a density of 1x106 cells per milliliter in sterile cryotubes. 
These cryotubes were snap frozen in liquid nitrogen and then stored at -70ºC. The 
cryopreserved Burkitt’s lymphoma cells were kept indefinitely as the propagatable cell 
stock.  
 
3.6 Cytogenetic  analysis of the cell lines. 
 
Confirmation of the karyotype of the two cell lines was carried out as previously 
described (Hozier and Lindquist 1980; Swansbury 2003). Pertinent steps in this 
karyotype confirmation process are outlined below. 
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3.6.1 Culture initiation.  
 
The cultured cell suspension was carefully decanted into a 15ml polypropylene tube 
and centrifuged at 1500rpm at room temperature for 8 minutes. Using a Pasteur 
pipette, the supernatant was carefully removed from the cell pellet and discarded 
leaving only 0.5ml of medium in which the cell pellet was resuspended. Five milliliters 
of a hypotonic solution ( 0.568g% KCl in sterile deionized water)  was added to the 
cell suspension and mixed. Fifty microlitres of clocemid  was added. The suspension 
was mixed well and incubated at 37ºC for 25 minutes.  
 
3.6.2 Cell harvest fixation.  
 
After 25 minutes of incubation, 3 drops of cold ethanol-acetic acid fixative (3:1 
mixture) was added drop by drop into the cell suspension using a Pasteur pipette and 
mixed well.  The suspension was centrifuged at 1500rpm for 10 minutes. The 
supernatant was removed and discarded leaving a small volume of fluid in which the 
pellet was resuspended. A further  5ml of the ethanol-acetic acid fixative was added 
slowly. The cell pellet was resuspended and centrifuged at 1500 rpm for 10 minutes. 
This fixation process was repeated until the supernatant was clear. If not analyzed 
immediately, the suspension was stored at -20ºC until slides were made.  
 
3.6.3 Preparation of slides. 
 
The stored cell suspensions were allowed to stand at room temperature for 15 
minutes. New, factory pre-cleaned, frosted slides were used. The chromosome 
separation seems to work best if the slides are chilled in the freezer first. Slides were 
placed side by side on paper toweling with no separation between them. The entire 
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content of the centrifuge tube was withdrawn into a Pasteur pipette. From a height of 
about 18 inches, two or three drops of fluid were dropped onto each slide. Slides were 
allowed to dry thoroughly at room temperature. Occasionally slides were placed in an 
incubator at 37ºC overnight to complete the drying process. The dried slides were 
stained with Giemsa for 7-10 minutes. Excess Giemsa was rinsed off with distilled 
water and slides air dried.  
Dried slides are mounted with DPX (glue) under a coverslip. The slide’s appearance 
was assessed under the microscope and recorded. Once the chromosomes have 
been prepared and mounted upon slides they are ready for analysis. 
 
3.7 Patient DNA extraction. 
 
Unstained and unfixed bone marrow aspirate smear slides from previously diagnosed 
Burkitt’s’ lymphoma patients were the source material for DNA extraction.  
 
Extraction was carried out using the method of Anderegg and colleagues (Anderegg, 
Schluter et al. 1998). Marrow was scraped off the glass slides with a sterile scalpel 
blade into a sterile 2ml Eppendorf tube. The scraped marrow sample was then 
suspended thoroughly in 300µl of lysis buffer with pH 8.8 containing 0.1M Tris/EDTA,  
and 1% sodium dodecyl sulphate (SDS) . Protein was digested with 30ng Proteinase 
K (Amersham, South Africa) at 56ºC for 60 minutes. RNA was removed by adding 6µg 
of RNAse A (Amersham, South Africa) and the tube inverted at least 25 times before it 
was incubated in a heated block at 37ºC for 15-60 minutes. The suspension was then 
cooled back to room temperature. Protein was then precipitated by adding 100µl of 
protein precipitating solution (Gentra Systems, Mineapolis, MN, USA. The tubes were 
mixed on a whirl mixer for 20 seconds and incubated on ice for 5 minutes. The protein 
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precipitate was then pelleted by centrifugation at 12 000g for 3minutes. The 
supernatant containing DNA was decanted into a clean sterile 2ml epppendorf tube. 
The suspended DNA was precipitated with 300µl of ice cold isopropanol. Where the 
DNA yield was visually perceived to be poor, it was improved by the addition of 20ng 
glycogen into the tube. The tube was inverted 50 times and the DNA pelleted  by 
centrifugation at 12 000g for 5 minutes. The DNA precipitate was washed with 300µl 
of ice cold ethanol. DNA was finally suspended in a suitable volume of TE buffer, at 
pH 7.5. Suspension was facilitated by subsequent incubation at 56ºC for up to 60 
minutes with gentle shaking. 
 
3.8 Control DNA extraction. 
 
Cells suspended in RPMI culture medium were pelleted by centrifugation at 5 000g for 
2 minutes. The cell pellet was transferred to a clean sterile 2ml Eppendorf tube. The 
cells were lysed and subsequently treated as described in the Andregg et al method 
described in section 3.7 above.  
 
3.8.1 DNA quantification and purity check. 
 
A sample of suspended DNA was diluted in TE buffer (10mM Tris, 1mM EDTA) to 
give an optimal density reading of less than one. The absorbance of the DNA sample 
was measured at 260nm and 280nm in an appropriately calibrated UV 
Spectrophotometer (Beckman DU6, GMI Inc, Minnesota, USA). The DNA 
concentration in the original tube was calculated using standard conversion factors. 
The ratio of DNA absorbance at 260/280 was calculated and used as measure of 
DNA purity.  The DNA was stored at -20°C until further analysis.  
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3.8.2 DNA agarose gel fractionation. 
 
A sample of DNA was mixed with sample loading solution and run on an 0.8% 
Agarose gel containing 0.5mg/ml Ethidium bromide. The resultant electrophoretogram 
was viewed and photographed under ultraviolet light. The size of DNA product was 
compared to known lambda DNA II size markers (Roche diagnostics, USA ). In 
addition, each DNA sample was carefully analyzed for evidence of degradation.  
Degraded DNA and DNA of low molecular weight were excluded from subsequent 
PCR analysis.    
 
Table 3.3   PCR master mixture preparation. 
Mixture components Final volume Final concentration 
 
Master Mixture1 
 
• Double distilled H2O 
• dNTP mixture† 
• Forward primer 
• Reverse primer 
• Template DNA 
 
Master Mixture 2 
• Sterile H20 
• Buffer 3 
• Enzyme mixture‡ 
 
 
 
 
to final volume of 25µl 
2.5µl 
4µl 
4µl 
4ul 
 
 
to final volume of 25µl 
5µl 
0.75µl 
 
 
 
- 
350µM each 
60pmol 
60pmol 
300ng 
 
 
- 
1.75mM 
2.5U/reaction 
†Contains equal proportion of dATP, dCTP, dGTP and  dTTP 
‡Taq/ Pwo DNA polymerase enzyme mix 
 
3.9 PCR master mixture preparation. 
 
Two PCR master mixtures comprising PCR reagents shown in table 3.3 were 
prepared as per Roche Expand Long template PCR System protocol (Catalogue 
number 1681842, Roche Diagnostics, USA). These were added in the order shown in 
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table 3.3 into a 200µl thin walled PCR tube. The master mixtures were then pooled 
and briefly vortexed before being put in a thermal cycler for amplification.   
 
3.10        tPA LD-PCR analysis of patient DNA. 
 
To establish the suitability of patient DNA for LD-PCR use, each patient DNA was first 
amplified with the tPA primer set as a control measure. The tPA primers were 
purchased from Roche Diagnostics and have been optimized for use with the Expand 
Long Template LD PCR system (Catalogue number 1691014, Roche Diagnostics, 
USA). The primer set properties are shown in Table 3.4. Primer preparation was done 
as described in table 3.3. The tPA LD-PCR analytical conditions were exactly the 
same as those for the t(8;14) and are described in table  3.6 below.  
 
Multiplex LD-PCR reactions were attempted in which the tPA and t(8;14) amplification 
reactions were done in the same tube. In most instances this approach proved to be 
problematic with inconsistent results. 
 
Table 3.4   tPA  LD-PCR primer properties. 
Primer name Primer sequence Annealing temperature 
tPa forward 7 5’-GGA AGT ACA GCT CAG AGT TCT GCA GCA CCC CTG C-3’ 65°C 
tPa reverse 10 5’-GAT GCG AAA CTG AGG CTG GCT GTA CTG TCT C-3’ 65°C 
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3.11 t(8;14) LD-PCR analysis of patient DNA.  
 
Each LD-PCR run included a blank sample with only reagents but no DNA material, 
CA-46 control DNA and  DAUDI control DNA. These controls were run with four 
separate primer pairs, namely, MYC-Cα, MYC-Cµ, MYC-Cy and MYC-JH primer 
pairs.  The MYC oligonucleotide was the forward primer and one of the four IgH 
oligonucleotides was the reverse primer. The primer properties are described in 
Figure  3.5 below 
 
DNA amplification was carried out in a Thermal Cycler 9600 ( Perkin Elmer, Norwalk, 
CT).  The reaction conditions were those described by Basso and colleagues  (Basso, 
Frascella et al. 1999) and are outlined in table 3.6 below. Both the t(8;14) positive and 
negative BL DNA were included as controls in each LD-PCR analysis.  
 
Table 3.5   t(8;14) LD-PCR primer properties. 
 
Primer 
name 
 
Primer Composition Primer Length 
Primer  
Tm 
MYC 5’-ACA GTC CTG GAT GAT GAT GTT TTT GAT GAA GGT CT -3’ 35-mer 67.1°C 
Cµ 5’-TGC TGC TGA TGT CAG AGT TGT TCT TGT ATT TCC AG - 3’ 35-mer 68.3°C 
Cy 5’-AGG GCA CGG TCA CCA CGC TGC TGA GGG AGT AGA GT-3’ 35-mer >75°C 
Cα 5’-TCG TGT AGT GCT TCA CGT GGC ATG TCA CGG ACT TG-3’ 35-mer 73.0°C 
JH 5’-ACC TGA GGA GAC CAG GGT GAC GGT-3’ 24-mer 67.8°C 
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μ γ α
μ μ ααγ γσμ
μ μ ααγ γσμ
  
 
Figure 3.1   Schematic representation of the t(8;14) with primer positions. The 
breakpoints in the MYC gene usually occur at exon 1or intron 1 whilst those in the IgH 
gene are variable and could occur in the JH gene, switch regions or constant regions. 
The t(8;14) result in the 5’-5’ orientation of the MYC and IgH gene segments with the 
consequent dysfunctional DNA segment. The positions of the five primers are shown 
by arrows. The upstream MYC gene primer was alternative paired with one of the four 
IgH primers ( Modified from Hecht and Asler 2000)  
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Table 3.6   LD-PCR analytical conditions. 
 
No of cycles 
 
Process 
 
Temperature & duration 
1 x 
 
Template denaturation 
 
94°C for 2min 
 
10 x  
Denaturation 
Annealing 
Elongation 
94°C for 10 secs 
65°C for 30 secs 
68°C for 4min 
20 x 
 
Cycle 1 Denaturation 
              Annealing 
              Extension 
Cycle 2-20 
94°C for 10secs 
65°C for 30secs 
68°C for 4min 
Denaturation and annealing the 
same as above, extension extended 
by 20secs/cycle 
1 x Final extension 68°C for 10 min  
Cooling Cooling 4°C until removed from cycler 
 
 
3.12 LD-PCR product quality check. 
 
A 0.8% Agarose gel containing 0.5 x TAE buffer and 0.5µg/ml Ethidium bromide was 
prepared as shown in table 3.7 below. Briefly, agarose was weighed in a weighing 
boat and transferred into a 250ml conical flask. An appropriate volume stock TAE 
buffer was added and the volume made up to required amount with water. Agarose 
was dissolved in a microwave and then cooled down to 50°C. Ethidium bromide was 
added and the gel was poured into the minigel system and allowed to set at room 
temperature for an hour.  
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Five microlitres of the PCR amplicon and molecular weight markers was sampled into 
an Eppendorf tube and mixed with sample loading buffer containing 25% Ficoll 400,  
0.25% Bromophenol blue and 0.25% Xylene Cyanol. The mixture was loaded into the 
agarose gel.  
 
Electrophoresis was carried out using a gel running buffer (1 xTAE buffer ) containing 
0.5ug/ul Ethidium bromide at 50-100volts.   
 
Table 3.7   Agarose gel preparation. 
Stock component 50ml final Volume 100ml final volume 
Agarose powder (g) 
(molecular biology grade) 
0.4g 0.8g 
Stock 50XTAE buffer 
(2M Tris acetate + 0.05M EDTA) 
500µl 1000µl 
Stock Ethidium bromide 10mg/ml 2.5µl 5µl 
Double distilled sterile water To 50ml To 100ml 
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4. CHAPTER 4 
4.0 RESULTS 
4.1 Study population selection. 
 
The study population was selected according to inclusion criteria defined in section 
3.1  above  and the selection process results are depicted graphically in Figure 4.1 
below. Between January 1994 and December 2003 there were 110 patients 
diagnosed with BL in the three teaching hospitals in Johannesburg. Eighty four (76%) 
of these patients had BL with bone marrow involvement whilst 26 individuals 
presented with other organ system involvement with no demonstrable tumor cells in 
the bone marrow. Archival bone marrow smear slides remaining after routine 
diagnosis were available in 74 of 84 (88%) identified BL patients. The 10 cases 
excluded were mainly as a result of all marrow slides being used up during the routine 
diagnostic workup with no remaining archival material.  DNA extraction  was 
performed in the 74 BL available patients with slides. Extracted DNA was either of 
extremely poor quality or quantitatively very small or absent in 23 of the 74 cases 
(31%). These cases were therefore not suitable for further analysis leaving only 41 
cases that could be analyzed with LD-PCR.  
 
4.2 Study population demographics.  
 
The demographics of the study population are shown in Figure 4.1 below. The mean 
age of the 41 patients included in the study was 21.4 years with a range from 3-60 
years. In the selected study population there was a slight predominance of males 
comprising 23 subjects (56%). Three quarters of study population comprise black 
subjects with only a third of patients being white. In terms of traditional divisions of 
care of patients using 15 years as a cut off, approximately an equal  
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Figure 4.1   Study population selection 
 
. 
  
  60 
 
Table 4.1   Study population demographics. 
Patient number Age   (years) Race Sex 
BL1 9 White Male 
BL2 19 White Male 
BL3 13 White Male 
BL4 32 Black Female 
BL5 8 Black Female 
BL6 45 Black Male 
BL7 36 White Male 
BL8 6 White Male 
BL9 6 Black Female 
BL10 24 Black Female 
BL11 60 Black Male 
BL12 32 Black Male 
BL13 28 Black Female 
BL14 22 Black Male 
BL15 51 Black Male 
BL16 6 Black Female 
BL17 25 Black Female 
BL18 58 Black Male 
BL19 9 Black Female 
BL20 10 Black Male 
BL21 14 Black Male 
BL22 8 Black Female 
BL23 32 Black Male 
BL24 6 White Female 
BL25 11 Black Male 
BL26 23 Black Female 
BL27 32 White Male 
BL28 25 Black Female 
BL29 22 Black Female 
BL30 47 Black Male 
BL31 50 Black Male 
BL32 35 Black Female 
BL33 23 Black Female 
BL34 4 White Female 
BL35 7 White Male 
BL36 8 Black Female 
BL37 8 Black Male 
BL38 11 White Male 
BL39 5 Black Female 
BL40 6 Black Male 
BL41 3 Black Male 
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number of patients were looked after by adult physicians and paediatricians ( 21 
versus 20 patients respectively)   
    
Patients were analyzed in the sequence in which they were identified and patient 
names in this table have been replaced with numbers to maintain confidentiality. 
 
4.3 Study population baseline laboratory parameters. 
 
The baseline laboratory parameters for patients in this study are shown in table 4.2 
below. The majority (29 of 41)(70%) of study participants were HIV negative by 
standard HIV Elisa tests and only 12 were HIV positive. The viral loads and CD4 
counts of the 12 HIV positive patients were unfortunately not consistently available in 
this retrospective analysis, with some patients having been tested for CD4 count or 
viral load but not both. By definition, all HIV positive patients had AIDS as per CDC 
criteria (Keou, Belec et al. 1992; Vella, Chiesi et al. 1994).  
  
The extent of bone marrow involvement, as measured by flow cytometric analysis, 
ranged from 4-97% with a mean of 57.9%. These figures correlated well with those 
obtained by morphologic examination. In general, bone marrow involvement 
evaluated by morphologic examination was slightly higher than the flow cytometric 
estimate on the same patient. This was largely due to Ficoll processing of specimen 
required for flow cytometry specimen preparation which resulted in some cell loss. 
There were no cases demonstrating diagnostic discrepancy between morphology and 
immunophenotypic analysis.  
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Table 4.2   Baseline laboratory parameters of study population. 
Patient 
number 
HIV 
status 
% BM 
involvement 
Immunoglobulin
Light chain CD19 CD10 
% S-
phase 
BL1 Neg 90.0 Kappa 90.0 90.0 ND 
BL2 Neg 80.0 Kappa 80.0 80.0 ND 
BL3 Neg 19.0 Kappa 26.0 46.0 ND 
BL4 Neg 85.0 Kappa 85.0 85.0 35.0 
BL5 Neg 91.0 Kappa 94.0 94.0 35.0 
BL6 Neg 90.0 Lambda 95.0 95.0 40.0 
BL7 Neg 80.0 Kappa 80.0 95.0 40.0 
BL8 Pos 34.0 Kappa 76.0 76.0 27.0 
BL9 Neg 35.0 Lambda 35.0 35.0 ND 
BL10 Pos 4.0 Lambda 16.0 16.0 ND 
BL11 Pos 94.0 Kappa 94.0 94.0 ND 
BL12 Neg 5.0 Kappa 5.0 5.0 ND 
BL13 Pos 7.0 Lambda 5.0 5.0 ND 
BL14 Neg 9.0 Kappa 9.0 9.0 ND 
BL15 Neg 9.0 Lambda 10.0 10.0 ND 
BL16 Pos 4.0 Kappa 5.0 5.0 ND 
BL17 Pos 30.0 Lambda 38.0 33.0 25.0 
BL18 Pos 77.0 Kappa 78.0 77.0 ND 
BL19 Pos 76.0 Lambda 76.0 76.0 43.0 
BL20 Neg 49.0 Lambda 56.0 56.0 35.0 
BL21 Neg 6.0 Kappa 6.0 7.0 ND 
BL22 Neg 8.0 Kappa 7.0 7.0 ND 
BL23 Pos 45.0 Lambda 66.0 55.0 ND 
BL24 Neg 65.0 Kappa 65.0 67.0 34.0 
BL25 Neg 80.0 Kappa 80.0 80.0 22.0 
BL26 Neg 65.0 Lambda 65.0 65.0 ND 
BL27 Neg 74.0 Kappa 74.0 74.0 54.0 
BL28 Pos 25.0 Kappa 25.0 25.0 ND 
BL29 Pos 80.0 Lambda 80.0 80.0 35.0 
BL30 Pos 82.0 Kappa 80.0 80.0 ND 
BL31 Neg 91.0 Kappa 91.0 91.0 50.0 
BL32 Neg 88.0 Kappa 88.0 88.0 44.0 
BL33 Neg 80.0 Kappa 80.0 10.0 ND 
BL34 Neg 54.0 Kappa 55.0 55.0 ND 
BL35 Neg 91.0 Kappa 91.0 91.0 40.0 
BL36 Neg 90.0 Kappa 90.0 90.0 ND 
BL37 Neg 91.0 Lambda 91.0 91.0 ND 
BL38 Neg 90.0 Kappa 90.0 90.0 ND 
BL39 Neg 24.0 Kappa 25.0 25.0 ND 
BL40 Neg 97.0 Kappa 95.0 95.0 ND 
BL41 Neg 80.0 Kappa 80.0 80.0 ND 
Key: Neg= negative , Pos= positive, ND= not done 
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Table 4.3   Cytogenetic findings of study population 
Patient number Cytogenetics for t(8;14) Other aberrations 
BL1 Neg  
BL2 Pos Trisomy 12 
BL3 Neg  
BL4 ND  
BL5 NG  
BL6 NG  
BL7 NG  
BL8 Neg  
BL9 Pos xxy 
BL10 NG  
BL11 NG  
BL12 NG  
BL13 NG  
BL14 Neg  
BL15 Pos  
BL16 NG  
BL17 NG  
BL18 NG  
BL19 NG  
BL20 NG  
BL21 Neg  
BL22 ND  
BL23 NG  
BL24 NG  
BL25 Neg  
BL26 Pos  
BL27 NG  
BL28 NG  
BL29 NG  
BL30 Neg  
BL31 Neg  
BL32 Pos  
BL33 NG  
BL34 Neg  
BL35 NG  
BL36 NG  
BL37 NG  
BL38 NG  
BL39 NG  
BL40 NG  
BL41 NG  
                      Key: Neg= negative , Pos= positive, ND= not done, NG=No growth  
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On immunophenotypic analysis, all BL cases demonstrated light chain restriction with 
the vast majority(71%) being Kappa rather than lambda light chain restricted. All BL 
tumors expressed CD10 and CD19 as well as other B-cell markers  
 
Aberrant marker expression by BL tumors was not reported. The majority (26 of 41) of 
the BL samples had no S-phase fraction analysis done. The s-phase fraction in the 14 
samples where it was performed was consistently above 20%. This finding is in 
keeping with the high grade nature of BL. All BL tumor cells in this study population 
were diploid by flow cytometric analysis with only two patients showing an additional 
aneuploid population. 
 
Although karyotype analysis was attempted in all samples, this analysis was largely 
unsuccessful due to consistent poor culture yield(24/41)(58%). The cytogenetics 
results are shown in table 4.3. Only five of the 41 patients in the study had the t(8;14) 
translocation demonstrable by cytogenetics. 
 
4.4 Burkitt’s lymphoma cell line culture results. 
 
The cell line culture was successful with no modification to the ATCC recommended 
culture conditions. At least 80% cell viability was consistently attained in every 
analysis of  culture undertaken. 
 
Table 4.4 below shows the typical viabilities of four cell line cultures done during the 
course of this study.  
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Table 4.4   Burkitt’s lymphoma cell line viabilities.  
Culture number Cell line Viability 
1 Daudi 88% 
2 CA46 90% 
3 Daudi 80% 
4 CA46 85% 
 
4.5 Culture storage and propagation. 
 
Cultures that were stored in DMSO were successfully propagated at various time 
intervals. The viability and culture behavior of these DMSO cryopreserved cell lines 
was not different from those of the original culture.   
 
4.6 Cytogenetic analysis of the Burkitt’s lymphoma cell lines. 
 
Table 4.5 below shows the results of confirmation karyotypic analysis of the two 
Burkitt lymphoma cell lines. The corresponding cell line chromosome analyses are 
illustrated in figures 4.2 and 4.3. The Daudi cell line had a normal chromosome 
complement as expected and the CA-46 cell line had the t(8;14) translocation 
depicted by arrows in Figure 4.3  
 
These cytogenetic results were reproducible over time indicating the stability of the 
cell lines  
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Table 4.5   Burkitt’s lymphoma cell karyotypic findings. 
Cell line Cytogenetic karyotypic findings 
Daudi original  cell line 46, XY  - normal male.  
Daudi subcultured cell line 46, XY - normal male 
CA46 original cell line 46, XY, t(8;14) - BL male 
CA-46 subcultured cell line 46, XY, t(8;14)- BL male  
 
4.7 Control DNA purity and yield. 
 
Significant amounts of DNA was extracted from control cell lines using the Anderegg 
method described in the previous chapter. The typical yield of the various extractions 
from 20 million cells is illustrated in Table 4.6 below. This DNA was of acceptable 
quality with minimal protein contamination as illustrated by the 260/280 absorbance 
ratio. The integrity, high molecular weight and RNA content of the extracted DNA was 
confirmed by running a 5µl sample on agarose gel containing ethidium bromide. This 
control DNA check is illustrated in Figure 4.4.   
 
4.8 Patient DNA extraction and quantification. 
 
As illustrated in Figure 4.1, DNA extraction was performed in 74 BL patients with bone 
marrow involvement. Extracted DNA was quantified and its protein contamination 
assessed by measuring the ratio of sample absorbance at 260nm and 280nm. In 41 of 
the 70 extractions, DNA was of high quality showing minimal degradation and RNA 
contamination. This DNA was therefore deemed suitable for subsequent LD-PCR 
analysis.  The successful DNA extraction and quantification is shown in Table 4.6 
below.  
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Figure 4.2   Giemsa stained chromosomes of the Daudi cell line. This karyotype  
is consistent with normal chromosome number and structure expected in the 
Daudi cell line.  Chromosomes 8 and 14 were normal in this karyotype 
analysis. 
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Figure 4.3   Giemsa stained chromosomes of the CA-46 cell line.  This karyotype 
shows the classic t(8;14) translocation which was expected in this cell line (shown by 
arrows). There were no other abnormalities noticeable on this karyotype. 
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Table 4.6  Control DNA extraction results. 
Cell line 
extractions 
Absorbance 
at 
260nm 
Absorbance 
at 
280nm 
Ratio  
of  
260/280 
DNA 
concentration 
µg/µl 
CA-46 
extraction 1 0.110 0.044 2.5 5.5µg/µl 
CA-46 
extraction 2 0.320 0.173 1.83 16.0µg/µl 
CA-46 
extraction 3 0.118 0.063 1.87 5.9µg/µl. 
DAUDI 
extraction 1 0.111 0.053 2.1 5.5µg/µl 
DAUDI 
extraction 2 0.256 0.143 1.8 12.8µg/µl 
DAUDI 
extraction 3 0.206 0.119 1.73 10.3µg/µl 
 
Notes: Extractions 1, 2 and 3 of the various cell lines were carried out at various time 
intervals from approximately six million cultured cells. Ten microlitres suspended DNA 
was diluted in TE buffer and its absorbance measured at two wavelengths                      
.Measurement at 260nm was for nucleic acids and measurement at 280nm was for 
protein contamination. The ratio of 260/280 represented the purity of the nucleic acid 
with an acceptable ratio in all extractions of more than 1.7. In patient samples an LD 
PCR product was possible even with a ratio of <1.7 
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Figure 4.4   Agarose gel electrophoresis of control DNA. Five microlitres of control  
DNA suspended in TE buffer was run in 0.8% agarose gel containing 1xTAE buffer 
and 0.5µg/µl ethidium bromide. Lane 1 is λ DNA II molecular marker ( Roche 
diagnostics). Lane 2 is healthy human volunteer control DNA. Lane 3 is the CA-46 
control DNA. Lane 4 is Daudi control DNA. All control DNA was of high molecular 
weight suitable for PCR analysis with no evidence of significant degradation or RNA 
contamination.  
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4.9 Patient DNA quality check. 
 
After quantification, 2µl of patient DNA was electrophoresed in a 0.8% agarose gel 
and photographed. Figure 4.5 shows examples of patient DNA that was intact and of 
high molecular weight suitable for subsequent PCR analysis as well as degraded DNA 
not used for subsequent analysis.  
 
4.10 The tPA LD-PCR analysis of control DNA. 
 
The CA-46 cell line was amplified using the tPA primers to check integrity and 
suitability of this control DNA for LD-PCR. The result of this analysis are shown in 
Figure 4.8 below. A single 4kb band was generated as an indication that the tPA gene 
in CA-46 was successfully amplified using LD-PCR. This analysis was also performed 
with the Daudi cell line which also showed successful amplification with similar 
fragment size. 
 
 
4.11 The combined t(8;14) and tPA LD-PCR  analyses of patient DNA 
 
LD-PCR analysis using two primer sets was set up as described in table 3.3 and 3.6 
above. The total reaction volumes and DNA amounts were adjusted accordingly. The 
result of this analysis is shown in Figure  4.6 below.  
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Figure 4.5   Agarose gel electrophoresis of patient DNA. Two microlitres of patient 
DNA dissolved in TE buffer was loaded on a 0.8% agarose gel containing 1xTAE 
buffer and 0.5mg/ml Ethidium bromide. Lane 1 is the λ DNA II molecular marker 
(Roche diagnostics, USA ). Lanes 2 and 5 are examples of high molecular weight 
patient DNA from patients BL6 and BL22 respectively. Lanes 3, 4, 6 and 7 are 
examples of poor quality partially degraded patient DNA that was not included in the 
subsequent PCR analysis. The dark bands in the middle and bottom of the gel 
(Marked with black stars) are the sample loading buffer dyes. 
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Table 4.7   Patient DNA extraction and quantification. 
Patient 
number 
Absorbance 
at 260nm† 
Absorbance 
at 280nm 
Ratio 
260/280 
[DNA]‡ 
µg/µl 
BL1 0.166 0.095 1.7 83.0 
BL2 0.119 0.09 1.3 59.5 
BL3 0.071 0.062 1.1 35.5 
BL4 0.101 0.085 1.2 50.5 
BL5 0.245 0.185 1.3 122.5 
BL6 0.227 0.163 1.4 113.5 
BL7 0.169 0.099 1.7 84.5 
BL8 0.176 0.126 1.4 88.0 
BL9 0.133 0.125 1.1 66.5 
BL10 0.033 0.027 1.2 16.5 
BL11 0.228 0.257 0.9 114.0 
BL12 0.301 0.198 1.5 150.5 
BL13 0.135 0.092 1.5 67.5 
BL14 0.37 0.277 1.3 185.0 
BL15 0.191 0.127 1.5 95.5 
BL16 0.145 0.085 1.7 72.5 
BL17 0.263 0.238 1.1 131.5 
BL18 0.19 0.16 1.2 95.0 
BL19 0.192 0.125 1.5 96.0 
BL20 0.12 0.08 1.5 60.0 
BL21 0.195 0.117 1.7 97.5 
BL22 0.445 0.263 1.7 222.5 
BL23 0.145 0.116 1.3 72.5 
BL24 0.107 0.1 1.1 53.5 
BL25 0.137 0.096 1.4 68.5 
BL26 0.087 0.075 1.2 43.5 
BL27 0.06 0.053 1.1 30.0 
BL28 0.235 0.178 1.3 117.5 
BL29 0.911 0.669 1.4 455.5 
BL30 0.156 0.117 1.3 78.0 
BL31 0.72 0.377 1.9 360.0 
BL32 0.48 0.393 1.2 240.0 
BL33 0.675 0.393 1.7 337.5 
BL34 0.945 0.521 1.8 472.5 
BL35 0.761 0.436 1.7 761.0 
BL36 0.129 0.064 2.0 64.5 
BL37 0.313 0.167 1.9 156.5 
BL38 0.152 0.102 1.5 76.0 
BL39 0.52 0.306 1.7 260.0 
BL40 0.331 0.194 1.7 331.0 
BL41 0.127 0.084 1.5 127 
†CONVERSION FACTOR : 1OD at 260nm = 50µg/ml dsDNA 
‡[DNA] is DNA concentration  
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Figure 4.6   The tPA and t(8;14) LD-PCR analysis of CA-46. The CA-46 cell line 
DNA was amplified using the tPA and MYC-Cα primers in separate tubes( 
Lanes 3 and 4) and multiplexed in a single tube ( Lane 7). The resultant 
amplicons were electrophoresed in a 0.8% agarose gel containing 1xTAE 
buffer and 0.5mg/ml ethidium bromide. Lane 1 is DNA molecular marker II 
(Roche Diagnostic, USA). Lane 2 is the reaction mixture without the Taq-PWO 
enzyme mixture. Lane 3 is CA-46 amplification using tPA primers. Lane 4 is 
CA-46 amplification using the MYC- Cα primer set. Lane 5 is the reaction 
mixture without DNA. Lane 6 is the reaction mixture without dNTPs. Lane 7 is 
LD-PCR using the tPA and MYC- Cα  in the same tube. 
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Figure 4.7   The tPA LD-PCR analysis of the CA-46 cell line. Two microlitre of DNA 
molecular marker II and LD-PCR amplicon was loaded on a 0.8% agarose gel 
containing 1xTAE buffer and 0.5mg/ml ethidium bromide. Lane 1 is the DNA 
molecular marker II showing the top six bands . Lane 2 is the CA-46 LD-PCR product 
using tPA primers.  The amplicon fragment size was approximately 4kb which was as 
expected. 
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Figure 4.8   Agarose gel electrophoresis of positive and negative controls. Following 
long distance polymerase chain reaction, 2µl of amplicon sample was loaded on a 
0.8% Agarose gel containing 1xTAE and 0.5mg/ml ethidium bromide. Electrophoresis 
was carried out at 100mA at ambient room temperature. Lane 1 is the Roche DNA 
molecular marker II. Lane 2 is the CA-46 LD-PCR amplicon using the MYC- Cα primer 
pair. Lane 3 is the CA-46 LD-PCR product using the MYC- Cγ primer pair. Lane 4 is 
the CA-46 LD_PCR product using the MYC- Cµ primer pair. The stars on lane 4 show 
two different bands using this primer pair. Lane 5 is the CA-46 LD-PCR product using 
MYC- JH primer pair. The circle shows the band which was much more visible on the 
gel than it is on the current photograph. Lane 6 is DAUDI LD-PCR using the MYC- Cα 
primer pair. This primer pair yielded no product as expected. 
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4.12 The t(8;14) LD-PCR analysis of patient DNA. 
Each patient LD-PCR analysis included positive and negative controls for the t(8;14) 
translocation. In addition to the tPA LD-PCR analysis, each patient t(8;14) LD-PCR 
was performed 4 times with each of the four MYC-IgH primer pairs.  
  
Following amplification, 2µl of the LD-PCR product was run on an agarose gel and 
analyzed for DNA degradation and product size. Figure 3.1 illustrates the t(8;14) 
translocation and positions of primers used in this study. As can be seen in this 
illustration, the products of the various primer sets have different lengths and therefore 
can be easily distinguished. It can be deduced from this figure  that , depending on the 
position of the breakpoints, the MYC-JH primer product should produce the shortest 
amplicon fragment size and the MYC-Cα product should be the longest fragment size. 
 
The results of the t(8;14) translocation and tPA LD-PCR analysis of  patient DNA are 
tabulated in Table 4.8. The tPA LD-PCR was positive in all 41 patients. In some 
instance, this positivity was confirmed on more than one occasion when repeat 
analysis was indicated.  
 
Only 6 of the 41 BL patients were positive for the t(8;14) translocation using all four 
primer sets. Two of these involved the JH region and there were two in the Cµ region. 
One occurred in each of the Cα and Cγ regions.   Attempts to correlate these patients 
PCR results with clinical outcomes were unsuccessful as 4 of the six patients had died 
and the archived clinical notes were incomplete in 3 of the six patients. 
 
.  
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Table 4.8   LD-PCR results using t(8;14) and tPA primers. 
Patient 
number 
tPA LD-
PCR result 
t(8;14) LD-
PCR 
result 
Region 
involved 
t(8;14)  LD-
PCR 
fragment 
size (kb) 
BL1  +  -     
BL2  + -     
BL3  + -     
BL4  + -     
BL5  + -     
BL6  + + JH 1.0 
BL7  + -     
BL8  + -     
BL9  + -     
BL10  + -     
BL11  + -     
BL12  + -     
BL13  + -     
BL14  + -     
BL15  + -     
BL16  + -     
BL17  + -     
BL18  +  + JH  1.2 
BL19  + -     
BL20  + -     
BL21  + -     
BL22  + -     
BL23  + -     
BL24  + -     
BL25  + -     
BL26  +  + Cµ 0.7; 1.5 
BL27  + -     
BL28  + -     
BL29  + -     
BL30  +  + Cµ 0.7 
BL31  +  + Cγ 3.6 
BL32  + -     
BL33  + -     
BL34  + -     
BL35  + -     
BL36  + -     
BL37  + -     
BL38  + -     
BL39  + -     
BL40  + -     
BL41  +  + Cα 4 
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CHAPTER 5 
5.0 DISCUSSION AND CONCLUSION 
5.1 General discussion. 
 
The most frequent genetic alteration in BL, accounting for 75-85% of the total, is the 
t(8;14)(q24;q32) translocation in which the MYC gene is juxtaposed to the IgH on 
chromosome 14 in divergent orientation (Basso, Frascella et al. 1999; Mussolin, 
Basso et al. 2003). Whilst PCR has revolutionarized the diagnostic approach of many 
lymphoproliferative disorders, the lesions in BL have not been amenable to analysis 
by this technique. The major limitation has been the distance between the breakpoint 
in BL being far so apart such that they not amplifiable by using standard Taq 
polymerase enzyme which can amplify up to 3kb DNA segments.   Recently, DNA 
polymerases with effective amplification of longer targets have been discovered 
(Hinnisdaels, Del-Favero et al. 1996). With these new high fidelity enzyme mix it is 
now possible to characterize the t(8;14) translocation in BL.  
 
In this retrospective molecular analysis, LD-PCR was established and optimized for 
the t(8;14) translocation using the commercially available LD-PCR system and BL 
lymphoma cell lines. The t(8;14) LD-PCR was then applied to a retrospective analysis 
of BL cases diagnosed in a period of 10 years from 1994 to 2003. 
 
5.2 Analysis of controls. 
 
In the establishment of a new assay, the critical importance of including controls 
cannot be overemphasized.  
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Appropriate BL controls were sourced from two cell lines, namely, the CA-46 with the 
t(8;14) translocation ( positive control) and the Daudi cell line without the t(8;14) 
translocation (negative). Culture of the two cell lines was reproducible and their 
growth and cytogenetic characteristics were confirmed. There were no additional 
chromosomal aberrations noted in the subcultured CA-46 and Daudi cell lines.  It is 
noteworthy that apart from the t(8;14) translocation, the original CA-46 description 
from ATCC included other cytogenetic lesions such as 13q+, +16 and duplication of 
chromosome 1 which were absent in the cell line stock we obtained.  The reasons for 
this are uncertain.    
 
The optimization of the t(8;14) assay was performed using the BL cell line DNA. As 
shown in Figure 4.4, high molecular weight normal DNA was also extracted. Normal 
DNA would have been insufficient to use alone in the absence of a t(8;14) positive 
control. High molecular weight non-degraded DNA was obtained from both patient 
samples and control cell lines as shown in figures 4.4 and 4.5. Unlike standard PCR in 
which almost any size DNA segment can be amplified, it was important to have large 
DNA segments for longer product synthesis in this LD-PCR assay. Therefore, the 
validation of DNA integrity and quality check was one of the critical steps in the 
analysis.  
 
As a result of this DNA quality concern, a large number of extracted DNA could not be 
used for subsequent analysis. Of the 74 BL patient samples in which DNA was 
extracted, only 41 passed this important validation step and were used for the 
subsequent LD-PCR assay. In the 23 BL DNA samples that could not be used, there 
were some that were completely degraded as shown in lanes 3, 4, 6 and 7  of figure 
4.5. Most of this degradation would appear to have occurred during storage of the 
bone marrow slides rather than during sample processing in this assay. This was 
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confirmed by analysis of the pattern of degradation which showed that it was more 
common in older slides and less common in recently stored bone marrow slides.  
Although DNA is known to be stable, storage degradation was not completely 
unexpected as all slides were stored uncovered at room temperature.  
 
 In the LD-PCR assay setup, the tPA LD-PCR gene analysis was included as an 
internal control. This served two purposes, namely, to establish the integrity and 
suitability of DNA for the assay,to exclude inhibition and also to validate the LD-PCR 
assay. Any sample in which the tPA gene could not be amplified was therefore 
excluded.  As illustrated in figure 4.8, the expected  tPA LD-PCR product was 
approximately 4.7 kb in this analysis. This is well within the expected published range 
of 4-7kb.  The tPA LD-PCR band had a slightly different electrophoretic mobility to the 
MYC-Cα primer product and therefore the tPA LD-PCR assay could be run in the 
same tube in a multiplexing reaction as shown in figure 4.7. For simplicity and cost 
saving, the tPA assay was done first in all samples and if successful, the same DNA 
sample and reaction conditions were repeated with the t(8;14) primers. Both the 
negative and positive control DNA sample were successfully amplified with the tPA 
primers. As illustrated in table 4.8 all patient DNA was also amplifiable with the tPA 
primers confirming the integrity of the DNA specimens and LD-PCR assay.  
 
In addition to the above controls, each LD-PCR assay had a blank tube included with 
each run. The blank control had all the assay reagents except for the template DNA. 
This was mainly done to detect contamination and non-specific exogenous DNA 
amplification. The inclusion of blank analysis is shown in lane 5 of figure 4.6 During 
the patient and control LD-PCR analyses, no blank tube assay was ever reported 
positive. This is an indication that consistency and reproducibility of the assay 
conditions was maintained and exogenous DNA contamination was well controlled.  
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 The ideal scenario would have been for each of the t(8;14) primers to have their own 
positive controls. The CA-46 cell line breakpoint was amplifiable with the MYC-Cα 
primer set. In the absence of suitable cell lines for the other three primer sets, it was 
felt that this would not be a problem in this retrospective analysis as all specimens 
available would be analyzed and positive patient DNA specimens would then be used 
as controls in future analyses. 
 
5.3 The t(8;14) LD-PCR analysis. 
 
Following appropriate selection and control analysis there were 41 BL patient DNA 
samples which could be evaluated by the t(8;14) LD-PCR technique.  Five LD-PCR 
analysis were performed on each of these DNA samples using first the tPA primers 
and then each of the four t(8;14) primer sets. In effect 164 different LD-PCR assays 
were performed with t(8;14) primers on the 41 BL specimen. With repeat analysis and 
inclusion of controls, well over 300 LD-PCR analyses were performed  in the analysis.  
 
In the presence of appropriate controls, only 6 of the 41 t(8;14) LD-PCR analyses  
yielded a product confirming rearrangement of the BL derived patient DNA. Each of 
these positive analyses was repeated at least once and therefore this step ruled out 
the possibility of false positive results and/or DNA contamination.  As shown in table 
4.8, two of these amplifications were with the MYC-JH primers and another two with 
the MYC-Cμ primers. Amplification with primers MYC-Cγ and MYC-Cα yielded was 
positive for one patient each.   
 
There was no obvious correlation of the t(8;14) LD-PCR positivity with age, gender, 
HIV status, extent of bone marrow involvement or quality of DNA. 
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In subject BL26, there was a correlation between the cytogenetic and PCR results 
which were both postive. Sublects BL 30 and BL 31 yielded a positive result on LD- 
PCR  but failed to demonstrate t(8;14) on conventional cytoenetics. This discrepancy 
might reflect the limitations of cytognetics which is reliant on fresh material with vialbe 
cells. On the other hand there were four cases which were LD-PCR negative but 
positive for the t(8;14) on cytogenetics. The reasons for this discrepancy are not clear 
but could include variable breakpoints which are not amenable to PCR amplification. 
 
The MYC-Cα primer product size was the largest as predicted from the schematic 
representation shown in figure 3.1. This MYC-Cα primer product size was comparable 
to that obtained with CA-46 cell line in other studies (Akasaka, Ohno et al. 1997; 
Basso, Frascella et al. 1999).    
 
Although there were no positive controls, the MYC-Cγ, MYC-Cμ and MYC-JH product 
sizes were in line with the predicted sizes on the schematic diagram.  
 
LD-PCR analysis of patient BL26 DNA yielded two products with the MYC-Cμ primer 
pair. The significance of these two bands is uncertain. They were reproducible on 
repeat analysis using a different sample of the same DNA with the same primer pair. 
Although also possible, the possibility of primer dimerization was considered highly 
unlikely. Ideally the specificity of these bands should have been confirmed on 
southern blot analysis using a myc-specific probe.   
 
The majority of patients (35 out of 41) with BL lymphoma in this study were negative 
for the expected t(8;14) translocation. The reasons for this finding are not clear but a 
number of possibilities exist.  
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It is possible that for this cohort of BL all the breakpoints are far upstream exon 2 of 
the MYC gene such that they are missed by the exon 2 specific upstream primer. As 
shown in Figure 1.2 these would be possible if the epidemiologic variants were largely 
eBL as opposed to sBL or AIDS-BL. The fact that Johannesburg is not regarded as a 
BL endemic region makes hypothesis highly unlikely. Most of the patients studied 
were indigenous South Africans by first and second name criteria which make the 
alternative explanation due to migration also less likely. 
 
  
Similarly, the breakpoints could be clustered far downstream of the immunoglobulin 
gene such that they are not picked up by the immunoglobulin primers used. Unlike the 
5’ end of the MYC gene in which many breakpoints up to 300kb have been 
characterized (Yano, Sander et al. 1993; Veronese, Ohta et al. 1995; Hoglund, 
Johansson et al. 1996; zur Stadt, Hoser et al. 1997; Felix and Jones 1998), 
breakpoints 3’ to the IgH gene have all been consistently shown to occur within the 
switch regions of the various immunoglobulin constant region domains (Adams, 
Gerondakis et al. 1983; Bernard, Cory et al. 1983; Pelicci, Knowles et al. 1986; 
Haluska, Tsujimoto et al. 1988; Shiramizu and Magrath 1990; Shiramizu, Barriga et al. 
1991)  
It is possible that BL in South Africa do have a different breakpoint to those described 
in Europe or  America. Gutiirrez et al analyzed chromosomal breakpoints in 39 cases 
from South America and shosed that the majority of breakpoints on chromosome 8 
occureed in the immediate flankng region of c-myc. These breakpoint were 5’ of the 
typical sporadic breakpoint in the first intron/exon region and 3” of the typical 
breakpoints described in eBL(Gutierrez, Bhatia et al. 1992) 
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The possibility that the low yield of t(8;14) could also be due to a technical problem 
was also considered. The primers with more than one positive result in the t(8;14) 
analysis are probably specific and functional. Those primers with just one positive 
result and no positive control make this possibility plausible. The large number of 
controls and consistently produced internal controls make the reagents and analytical 
process unlikely explanations. The template DNA in all instances was of high quality 
and integrity. 
 
5.4 Limitations of the study. 
 
The design of this study, being a retrospective analysis, was a major limitation. 
Although analysis from stored slides would be an advantage, this storage is 
associated with gradual deterioration of template DNA for analysis. A large number of 
slides had varying degrees of DNA degradation with up to 23 BL excluded on the 
basis of the poor quality of the DNA. In addition to poor quality, not all BL slides were 
available for analysis.  
 
The fact that there were no positive controls for some the t(8;14) primer sets is also a 
limitation. Ideally all primer amplification products should be correlated with 
appropriate positive and negative controls. At the time of study initiation, cell lines with 
positive controls for the Cμ, Cγ and JH regions were not easily obtainable. Reliance 
on obtaining patient positive control is probably acceptable but not the best practice. 
Other studies such that by Basso etal (Basso, Frascella et al. 1999) have used cell 
lines which were positive for all the regions of the IgH as appropriate controls. These 
cell lines are not easily available and efforts to obtain at the time of the study proved 
fruitless. 
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Each analysis had to be done five times which made this LD-PCR particularly labour 
intensive. The impact would be particularly evident if one or two samples are  
analyzed as opposed to the 41 samples that were done at the same time in this study. 
Sequential analysis of the samples with different primer sets would be an alternative 
however this option impacts negatively on analytical turnaround time. 
 
Ideally, positive samples should have been confirmed with sequencing or Southern 
blot analysis and hybridizaton to a MYC oligonucleotide probe. This would have 
conclusively confirmed the specificity of the amplicon fragments obtained with LD-
PCR analysis. The analytical costs and labour intensive nature of southern blot 
analysis and sequencing precluded this essential step. 
 
The biggest limitation by far is the inability of this assay in our hands to confirm the 
t(8;14) translocation in BL with an otherwise well established diagnosis. Whether this 
represents a variant of BL requiring a completely different primer set or due to any of 
the reasons discussed above remains uncertain. What is certain however is that this 
LD-PCR in its current form cannot be used for routine diagnosis of BL. By implication 
this excludes its utility in minimal residual disease detection and minimal disseminated 
disease detection. 
 
The inability of LD-PCR to pick up the BL translocation is not unique to this study. 
None of the previous studies have been able to identify all known BL. In the three 
studies reviewed in chapter 1, the diagnostic sensitivity of LD-PCR was variable 
ranging from 55% to 87% (Shiramizu, Barriga et al. 1991; Akasaka, Ohno et al. 1997; 
zur Stadt, Reiter et al. 1997; Mussolin, Basso et al. 2003). A significant proportion of 
BLs could not be diagnosed using LD-PCR in these studies.  
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5.5 Alternative diagnostic modalities for  BL. 
 
The last study on t(8;14) LD-PCR was published in 2003 (Mussolin, Basso et al. 
2003). The limited number of studies published and absence of further studies on the 
diagnostic utility of the t(8;14) LD-PCR in the face of growing popularity of the PCR 
technique could perhaps be an indirect indicator of the poor diagnostic utility of this 
approach. In the interim, a number of other diagnostic tools for the t(8;14) lesions are 
beginning to emerge and these include the Fluorescence in situ hybridization (FISH) 
and microarray gene profiling analyses. 
 
Fluorescence in situ hybridization (FISH) analysis for the t(8;14) has become a 
popular  tool for studying cytogenetic lesions in BL. The advantage of FISH in BL 
analysis is its ability to identify not only the t(8;14)  but also the t(2;8) and t(8;22) 
translocations. In a recent analysis of fixed paraffin embedded tissue sections for 
t(8;14) , 100% of the translocations were identified by an automated FISH procedure. 
(Reichard, Hall et al. 2006). Although FISH lacks the sensitivity of PCR in the 
detection of minimal residual disease, this technique is likely to be the tool of choice 
for diagnosis of cytogenetic lesions in BL. 
 
More recently, microarray gene profiling using BL molecular signatures has also 
become available. Although experience with BL gene profiling is still at its infancy and 
limited, evidence from recent studies suggest that BL microarray analysis could 
provide superior molecular subtyping of BLs compared to current morphologic  and 
immunophenotypic approaches (Dave, Fu et al. 2006; Hummel, Bentink et al. 2006). 
The BL molecular signature is also useful in accurately distinguishing BL from DLCL, 
an important distinction to be made for planning therapeutic intervention in these 
conditions. The biggest advantage of the microarray approach is its ability to correctly 
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identify all BL including those with atypical morphology as well as those without 
demonstrable myc-immunoglobulin BL translocations (Dave, Fu et al. 2006; Hummel, 
Bentink et al. 2006). The latter is particularly important in the context of this LD-PCR 
study which failed to demonstrate the t(8;14) in the majority of known BLs. It is 
possible that the t(8;14) translocation may be inferior to the BL molecular signature for 
the diagnosis of all subtypes of  BL.  
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5.6 CONCLUSION. 
 
In this molecular analysis of BL, LD-PCR was established and optimized using t(8;14) 
positive and negative BL cell lines. Subsequent retrospective analysis of t(8;14) 
translocation resulted in an extremely poor yield in a sample of known BL. In our 
hands, t(8;14) LD-PCR  performance is unacceptably poor, labour intensive and costly 
making it  unsuitable for routine diagnostic use. Other diagnostic tools such as FISH 
and microarray analysis are starting to show superior diagnostic yields and could 
become the tools of choice for BL diagnosis, prognostication and therapeutic 
monitoring in future. 
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